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II.    ABSTRACT 
 
Sodium retention with suppressed plasma renin activity (PRA) is more common 
in black subjects of African ancestry compared to white subjects and is 
associated with an increased propensity to the development of hypertension. 
This thesis investigates whether such low renin status might be secondary to 
reduced availability of endothelium-derived or other peri-renal tubular source of 
nitric oxide (NO). The association of flow-mediated dilation (FMD, a measure 
of the vasomotor response to endothelium-derived NO) to PRA was examined 
in a group of asymptomatic subjects (n=143) of African/African-Caribbean 
(n=84, classified as “Black”) and White European (n=59) self-defined ethnic 
groups. The effects of a change in salt intake on FMD were examined in a sub-
set of 21 subjects and effects of inhibition of NO synthase on urinary sodium 
excretion were examined in a sub-set of 40 subjects. FMD was positively 
correlated with PRA, independent of age, gender, Black/White ethnicity, 24-
hour urinary sodium excretion and blood pressure (standardised regression 
coefficient, β= 0.32, P<0.002; FMD, 4.2±0.8% vs. 7.3±0.7%, in subjects with 
PRA < 0.5 and > 1.0 ngml-1hr-1respectively, P<0.0001).  Change in salt intake 
over a two-week period did not significantly influence FMD. NG-monomethyl-
L-arginine (L-NMMA) reduced fractional urinary sodium excretion whereas 
saline placebo was without an effect.  The anti-natriuretic effect of L-NMMA 
was positively correlated with PRA (P<0.01, 3.4±7.0% % vs. 29.6±5.5% 
reduction in fractional sodium excretion in subjects with PRA < 0.5 and > 1.0 




asymptomatic subjects, renal sodium excretion is regulated by endothelium-
derived or other peri-tubular source of NO. Reduced NO availability may 
underlie sodium retention and increased vascular risk associated with the low 
renin phenotype. Treatment with NO donors and/or enhancement of 
endogenous NO availability might be beneficial in subjects with low renin 
status. Further studies are required to explore the association of NO availability 
with sodium homeostasis in different groups (e.g. those with hypertension) and 
to test effects of interventions to modulate NO availability on sodium 
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1.1 Epidemiology of Cardiovascular Diseases and  
Hypertension 
 
In the last half century, and exponentially in the last two decades, the global 
focus on health and health care delivery has shifted from the infectious diseases, 
such as dysentery, rheumatic fever and polio, to chronic non- communicable 
diseases (NCDs); the so called “lifestyle diseases”. This transition has seen both 
the creation and implementation of several government funded organizations, 
such as the United States Centre for Disease Control and Prevention (CDC), 
aimed at changing regional, national and international policy to address the two-
fold rise of cardiovascular disease (CVD) in the next decade (Kearney, 2005). 
The explosion of NCDs over the last decade has led to the establishment of 
global targets in the fight against the current trajectory; the World Health 
Organization (WHO) 2025 nine strategic targets is an example of such a policy 
(WHO Authors, 2013). 
 
CVD accounts for the largest percentage of the NCDs (Lim, 2012). It therefore 
represents an enormous health and socioeconomic burden for both mortality, 
but more seriously morbidity, in terms of personal and financial cost. It is 
likely, therefore, to be the most substantial health challenge of our century 
(Yusuf, 2001; Reddy, 2004). In the USA, an estimated eighty million 




estimated that this figure may be as high as 1 in 2 persons for Americans over 
60 years of age (Mozaffarian, 2015). Myocardial infarction (MI) and 
cerebrovascular accidents (CVA) have substantially increased in the both the 
USA and the UK, though concomitant improvements in health care delivery 
have led to a decline in the mortality associated with these conditions 
(Beaglehole, 2011). There has been, however, a noticeable increase in 
morbidity across all ages with increased mortality rates among people less than 
40 years (Alwan, 2010). It is thought that this has resulted primarily from a 
concomitant increases in the traditional risk factors for CVD; hypertension, 
diabetes mellitus and hypercholesterolemia. Unidentified novel risk factors may 
also play a pivotal role in explaining the changing epidemiology of CVDs – 
including peripheral arterial disease (PAD) and coronary artery disease (CAD) 
(Ridker, 2001). This cascade of modifiable risk factors may be interacting with 
non-modifiable factors, such as age and ethnicity, to accelerate disease 
processes in particular groups with higher morbidity and mortality rates.  It has 
been observed in both the United Kingdom and the USA that an ethnic 
disparity exists with minority ethnic groups, especially black Caribbean people, 
having higher rates of certain CVDs than their Caucasian peers (Cruickshank, 
2001). This difference is unlikely to be explained solely by differential access 
to health care experienced by the middle to lower income (minority ethnic) 
groups. One key barrier to addressing the CVD challenge is the identification of 
particular differences in its epidemiology in minority ethnic groups. In 2005, 
the American Society of Hypertension (ASH) revised its definition of 




result in both structural and functional changes in the heart and vascular 
system.  
 
The prevalence of hypertension varied in one study between 23 – 52% between 
six middle-income countries (Basu, 2013). This is forecasted to result in the 
mortality of some 9 million people globally (WHO, 2013). Unfortunately, 
without targeted interventions aimed at reducing its prevalence, CVD is 
expected to have a significant impact on the socioeconomic development of 
societies worldwide (Kearney, 2005). This will be especially true for 
developing countries, including the Caribbean (Chaturvedi, 1993), which 
account for sixty five per cent of the global population (Lane, 2001) of people 
with hypertension; that is currently six hundred and thirty nine of nine hundred 
and seventy two million people. This unbalanced proportion further contributes 
to the disease burden for which reduced health budgets are disproportionately 
matched. These so called lifestyle diseases, are sometimes referred to as the 
“silent killers”, and are by far the number one cause of death in the Caribbean 
region. To this end, the interest in hypertension and CVD risk has lead to the 
establishment of several national and regional guidelines aimed at improving 
measures for their prevention and treatment. The region has also established the 
civil society interest group, the Healthy Caribbean Coalition, which was 
conceptualized out of the 2008 Port-of-Spain declaration. The latter was a 
regional statement by Caribbean member states aimed at addressing the 
increased burden of NCDs. The impact of lifestyle disease is also observed in 
the multi-ethnic area of South East London (Cappuccio, 1997). Current 




by the epidemiological data and take into account not only age, gender and 
additional risk factors like diabetes mellitus and hypercholesterolemia, but also 
the differences observed between ethnic groups. This stratification of risk and 
treatment options is likely to have significant impact on the cardiovascular 
























1.2 Epidemiology of Ethnic differences in CVD and  
         Hypertension 
 
It has been described that Africans and Afro-Caribbean people have a relatively 
higher prevalence of stroke and end stage renal disease than White Europeans 
despite having a lower incidence of coronary artery disease (Tillin, 2012). This 
ethnic difference may relate in part to the relative differences in risk factors 
between the two ethnic groups; a higher prevalence of both hypertension and 
diabetes is observed in the Black ethnic group. One study has also shown a 
significantly increased risk of glucose intolerance, diabetes and insulin 
resistance in Black and South Asian people living in the UK (Basu, 2013).  
Compared to White Europeans, people of Black Caribbean origin living in the 
UK have significantly lower concentrations of very low-density lipoproteins 
(VLDL), small dense low-density lipoproteins (LDL), triglycerides, and central 
obesity (Mora, 2007) and this difference has been observed as early as 5-6 years 
of age (Whincup, 2010). This contradicts the accepted paradigm that insulin 
resistance is associated not only with glucose intolerance but also central 
adiposity. Reduced rates of smoking and increased levels of high-density 
lipoproteins (HDL) have been calculated to reduce the risk of IHD by twenty 
five percent. This may however be negated by the increased risk of twenty five 
per cent observed in this ethnic group because of hypertension.  
 
In contrast to the incidence of IHD observed in Afro-Caribbean and African 
origin populations living in the UK, the relative risk of stroke is thought to be 




rates higher in Black Afro-Caribbean people in the UK compared to White UK 
nationals (Smeeton, 2011). This difference observed in the Black ethnic group 
appears to be independent of the origin of the host population; as shown with 
Afro-Americans born in the USA compared with those born in the Caribbean 
(Chaturvedi, 1993). Another explanation for the difference observed is not only 
the higher blood pressures seen in this group but also the reduced or absence of 
nocturnal fall in blood pressure – the so called “dipping”. This results in a 
whole day sustained exposure to higher pressures when compared to other 
ethnic groups (Cruickshank, 1980). One possibility is that the loss of “dipping” 
may reflect central arterial stiffening, measured as increased aortic pulse wave 
velocity (PWV). Ongoing work is testing this hypothesis; earlier data showed 
that PWV was powerfully predictive of mortality, independent of and even 
displacing blood pressure, including in these ethnic groups (Cruickshank, 2002; 
Vlachopoulos, 2010). This difference in stroke risk between Black and White 
people is true for all subtypes of stroke but is particularly pronounced for 
haemorrhagic stroke. The stroke register within one South East London 
community suggests an incidence rate ratio of 5.04; 95% CI, 2.54 – 9.97 for 
haemorrhagic stroke in Black versus White people (Cruickshank, 1980; 
Sharma, 1999). Haemorrhagic stroke is the stroke sub-type most strongly 
related to blood pressure and Black versus White differences in stroke risk may 
be explained in part by differences in the prevalence and severity of 
hypertension (Chaturvedi, 2003). The higher hypertension rates observed in 
black participants are associated with other CVD risk factors, which increase in 





The United Kingdom Prospective Diabetes Study (UKPDS trial group, 1994) 
showed lower rates of peripheral vascular disease (PVD), in particular 
peripheral arterial disease (PAD), in Afro- Caribbean people compared to the 
rest of the population. Such first generation migrants are now approaching the 
six and seventh decades of life and so complications of IHD, like congestive 
heart failure (CHF), are likely to have a major impact on both mortality and 
morbidity. 
 
Although several studies in the UK, Europe and North America report a higher 
prevalence of hypertension in Black vs. White people (Chaturvedi, 1993; 
Whitty, 1999), this ethnic difference was not observed in others (Manatunga, 
1993; Cruickshank, 1983). In London, the best estimate of the prevalence ratio 
of hypertension in Black compared to White people is 2.6 (Meade, 1978). For 
Black people who have migrated to the UK, it is thought that an additional 
“migration factor” might play a role in influencing the statistics (Tillin, 2012). 
This difference, not only in the rate of hypertension, but also the type of end 
organ damage, has led to significant differences in the morbidity and mortality 
of CVD. In particular, the type of hypertension, low renin hypertension, 
observed more frequently in this group may account for the major differences 









1.3 Renin and Salt Homeostasis  
 
As mentioned in 1.2, the prevalence of low renin hypertension in Black people 
living in London is higher when compared to white people. Renin is a 
polypeptide hormone secreted by the kidney in response to physiological 
changes in sodium concentration (Sancho, 1976). The renin angiotensin 
aldosterone system (RAAS) plays a pivotal role in sodium homeostasis by 
regulating its excretion by the kidneys (Poch, 2001). It does this, in part, in 
response to the sodium concentration and systemic pressure detected by the 
kidneys (Weir, 1999). The plasma concentration of sodium is therefore 
regulated to remain between physiological limits of 135 – 145 mmol/L. The 
significance of this is probably not only related to the risk associated with 
hypertension but also the likelihood of accelerated arteriosclerosis through a salt 
mediated mechanism (Brewster, 2003). As sodium is consumed in the diet, 
mainly NaCl, a negative feedback mechanism triggers a fall in renin secretion. 
To understand how this system works, knowledge of the physiological handling 
of sodium by the kidneys and its functional unit, the nephron, is required.  
 
1.3.1   The Nephron and Salt Handling 
The kidney nephron is the functional unit of filtration and represents a 
sophisticated system of blood capillaries and tubules producing an ultra-filtrate 
which can then be further manipulated to produce varying concentrations of 
electrolytes. The highly convoluted structure of this delicate network of blood 
vessels allows for an increased surface are for the filtering of blood under 




kidneys produce, on average, approximately 180 L of filtrate, which after 
reabsorption of water and solutes produces 1.5 L of urine per day. A diagram of 






















Figure 1: Diagram of the Nephron and Sodium Reabsorption sites  
(From Berne & Levy Principles of Physiology 4th Edition) 
 
 
Blood arrives at the glomerulus at the afferent arteriole and leaves this capillary 
tuft via the efferent arteriole. The system’s two main properties are a relatively 
high surface area to volume ratio and a pressure difference across the afferent 
and efferent arteriole to produce the hydrostatic pressure required for filtration 
across the capillary basement membrane. The ultra-filtrate produced traverses 
the Bowman’s capsule and continues distally through the proximal convoluted 
tubule (PCT); approximately sixty-five percent of the reabsorption of Na occurs 
here by active reabsorption via the Na+- K+ ATPase sodium pump. This solute 
shift results in the iso-osmotic reabsorption of water, the end result being that 
more than seventy percent reabsorption of the ultra-filtrate occurs. The filtrate 
continues through the loop of Henle (LoH) where approximately twenty five 
percent of the filtered sodium is reabsorbed. In the thick ascending limb (TAL) 
of the LoH, a Na-K- 2Cl cotransporter ion channel is responsible for the 




dependent on the re-entry of K+ back into the tubular lumen by another channel 
called the rectifying outer medullary K+ channel (ROMK) and the intracellular 
Na+ gradient generated by the interstitial Na+- K+ ATPase. The TAL is 
impermeable to water and so concomitant dilution of the tubular content occurs. 
This results in the concentration of filtrate as it flows down the descending limb 
of the loop that, unlike the TAL, is fully permeable to water.  The filtrate then 
enters the distal convoluted tubule (DCT) where another ion channel, the Na-Cl 
cotransporter (NCCT), causes the further dilution of urine. The final regulation 
of Na occurs in the collecting tubules. Firstly, under the action of antidiuretic 
hormone (ADH) water is reabsorbed via transmembrane water channels called 
aquaporins that allow water to leave the lumen along its osmotic gradient. 
Secondly, Na reabsorption (2 – 3%) occurs across the epithelial sodium channel 
(ENaC). This channel is under the direct action of the mineralocorticoid 
aldosterone, which in turn is largely regulated by the renin angiotensin system 
(RAS) (Ritter,  Textbook of Clinical pharmacology 5th Edition).  
 
1.3.2 The Renin Angiotensin Aldosterone System (RAAS) 
Renin is secreted in response to the relaxation of smooth muscle cells of the 
afferent arterioles of the kidneys in response to a decrease in glomerular 
perfusion pressure. There is a further sensing mechanism triggering renin 
release via the sensing mechanism of the macula densa cells of the 
juxtaglomerular apparatus to NaCl as shown in Figure 2. This results in renin 
release under conditions of reduced blood flow to the afferent arteriole and 














Figure 2: Diagram of the Juxtaglomerular Apparatus of the Nephron 
(From Berne & Levy Principles of Physiology 4th Edition) 
 
 
An outline of the RAAS is illustrated in Figure 3. Renin causes the cleavage of 
angiotensinogen to angiotensin I. The latter is then converted to its biologically 
active form as Angiotensin II. Angiotensin II, a potent vasoconstrictor, causes 
the release of aldosterone from the zona glomerulosa cells of the cortical 
adrenal gland. It also causes the release of ADH by the posterior pituitary 
gland, which results in the reabsorption of water from the collecting tubule.  
Both aldosterone and angiotensin II result in the reabsorption of Na from the 
DCT thereby decreasing the filtered load of Na. The increase in Na and water 
reabsorption results in an increase in the circulating plasma volume and this 
provides a negative feedback for renin release by increasing the renal perfusion 
pressure (Levy, Principles of Physiology 4th Edition). 
 
The sodium channels in the DCT are now thought to be also under the direct 
influence of NO, as described in section 1.3.3, causing the excretion of Na and 


















Figure 3: Diagram of the Renin Angiotensin Aldosterone System 
(From Berne & Levy Principles of Physiology 4th Edition) 
 
 
1.3.3   Nitric oxide and Sodium Excretion 
It has been well appreciated that NO plays a critical role in the excretion of Na 
and water by the kidney by regulating glomerular filtration rate (GFR). It is, 
however, only recently that its role in the regulation of solute control, 
particularly Na, has been elucidated (Mattson, 1996; Stoos, 1995). In vivo 
experiments have shown that the stimulation of NO production results in an 
increase in the urinary Na content (Stoos, 1995), despite relatively little or no 
change in the GFR. It is now thought that NO produced by the TAL inhibits the 
luminal Na-K-2Cl cotransporter by inhibiting the chloride current (Jcl) 
generated by this pump. The origin of the NO produced was further confirmed 
by the use of NO-specific measurements; NO- specific fluorescent dye and NO 
selective electrodes (Bachmann, 1994).   It is still controversial as to the role of 




the lumen, in the inhibition of the Na-K-2Cl co-transporter (Herrera, 2006).   
Prolonged (two hours) exposure of the energy dependent Na+- K+ ATPase pump 
to NO resulted in a reduction in the pump activity by 32% but in vivo studies 
have not been confirmatory (Guzman, 1995). NO is also thought to increase the 
expression of the co-transporter in the TAL. One experiment has shown a 
reduction in Na-K-2Cl channel number after an infusion of NG-nitro-L-arginine 
methyl ester (L – NAME), a NOS inhibitor. NO inhibition of the Na-K-2Cl co-
transporter is thought to be mediated by its production of cyclic guanosine 
monophosphate (cGMP) (Guzman, 1995).  
 
The NO produced by the TAL is thought to be due to the endothelial NOS 
isoforms (eNOS or NOS3) and this is also influenced by endothelin-1 binding 
to its receptor in the TAL; the ETB receptor. A high salt diet has been shown to 
transiently increase (approximately 3 days) the level of NOS3 in the TAL with 
return to baseline after 28 days (Mattson, 1996). It is speculated that prolonged 
exposure to a high salt diet may lead to reduced levels of NO. Studies are still 
on going to ascertain the precise mechanism of the effect of a high salt diet on 
NO dependent inhibition of the Na-K-2Cl co-transporter. 
 
1.3.4 Nitric oxide and Renin 
Renin, a protease, is secreted from the juxtaglomerular granular cells (JGG) of 
the afferent arteriole of the glomerulus. These cells are thought to have 
developed from the morphological change of the arteriole’s medial smooth 
muscle cells; a process, which is dynamic, and under the influence of Na 




(Thorup 1996). The synthesis and secretion of renin is under the direct control 
of the rate of sodium intake, the renal perfusion pressure and the circulating 
levels of angiotensin II (ANG II). Under conditions of increased NaCl reaching 
the adjacent macula densa cells, there is an inhibitory signal to the JGG thereby 
decreasing renin release. This signal has not been identified but is referred to as 
the “macula densa signal” and is thought to be a critical inhibitor of renin 
release. There is a high concentration of both NOS1 (nNOS) and NOS3 (eNOS) 
in the macula densa cells and endothelial cells respectively. It is thought that 
NO may serve as a buffer in this tubuloglomerular feedback system as 
demonstrated in studies utilizing NO inhibitors where the  NaCl – renin release 
phenomenon was impaired (Mundel, 1992). This influence appears to be related 
both to the dose and the duration of exposure to the inhibitor. There is also 
impairment of renin JGG production with the chronic inhibition of NOS3 by the 
macula densa cells. This was observed after chronic NOS inhibition caused 
significant reduction in the NOS3 gene and protein expression (Beierwaltes, 
1995). This may explain the diminution in, not only salt excretion, but also 
vascular tone and haemodynamics observed in low renin states, since NO is 
known to be a key player in both events (Beierwaltes, 1995). Alternatively, 
rather than a direct influence of NO on renin release, the influence of NO on the 






1.4 Vascular Haemodynamics and Hypertension 
 
1.4.1 Nitric Oxide and Endothelial Function 
The endothelial cell layer represents a dynamic biologically active layer under 
the direct control of various substances (Tolins, 1991; Shepherd, 1991). Nitric 
oxide is one such biologically active molecule concerned with the modulation 
of arterial tone. To this end, the molecule is produced by the endothelium and 
has both an autocrine and paracrine mode of action (Fosteran, 2006). Vascular 
tone is regulated, in part, by factors causing vasodilatation and those causing 
vasoconstriction. Endothelial cells produce NO by means of endothelial nitric 
oxide synthase (eNOS or NOS3). The presence of the enzyme is therefore of 
critical importance in the regulation of basal vascular tone. Under the action of 
eNOS, NO and L-citrulline are produced from the amino acid L–arginine. The 
release of NO by the endothelium is triggered by increases in the shear stress on 
the endothelium as shown in Figure 4. NO plays a critical role in maintaining 
vasodilation in the basal state and during exercise (Kalliokoski, 2006). Vascular 
NO causes vasodilation through cGMP mediated smooth muscle relaxation. 
Two other isomers of NO have been discovered to date: inducible nitric oxide 
synthase (iNOS or NOS2) and neuronal nitric oxide synthase (nNOS or NOS1) 
(Shah, 2000). NO not only serves as a vasodilator, but also has a number of 
potentially anti-atherogenic actions such as inhibition of platelet activation, 
inhibition of the expression of adhesion molecules and inhibition of the 
















Figure 4: Diagram showing Ca2+ and NO mediated FMD 
(Textbook of Human Physiology 10th Edition) 
 
 
1.4.2 Endothelial Dysfunction in Hypertension and  
Atherosclerosis 
Endothelial dysfunction is said to occur when there is a disruption of the 
balance between endothelium-derived vasodilation and vasoconstriction. There 
is evidence that this might occur in both HTN (Bolad, 2005) and in 
atherosclerosis (Charakida, 2006). In spontaneously hypertensive rats it has 
been shown that there is decreased expression of eNOS and hence a blunting of 
the NO-cGMP mediated relaxation of blood vessels. Atherosclerosis results 
from a cascade of events beginning with endothelial dysfunction and 
concluding with the production of an atherosclerotic plaque. There is decreased 
expression of eNOS in humans with developed atherosclerosis (Charakida, 




the process of atherosclerosis. Hypercholesterolemia, one of the known risk 
factors for atherosclerosis, is associated reduced availability of endothelium-
derived NO and this is also associated with other risk factors including diabetes 
mellitus and chronic cigarette smoking (Li, 2014). 
 
1.4.3   Increased Arterial Stiffness: Increased Peripheral and  
Central Systolic BP 
Arterial stiffness is a poorly defined entity in the scientific literature. Conduits 
that are described as “less stiff” are described as having a greater degree of 
compliance. Compliance is defined as the resultant change in volume (V) for an 
accompanying change in pressure (∆ P) (Sharma, 2012). Such that: 
Compliance = ∆V / ∆ P 
Blood vessels are described as distensible (or less stiff) when there is a greater 
fractional change in the diameter (D) caused by a given pressure (Nichols, 
1998): 
Distensibility = ∆ D/ (D.∆P) 
The inverse of this equation is a measure of arterial stiffness and is defined as 
the Peterson’s elastic modulus, EPeterson  (Peterson, 1960): 
EPeterson= (D.∆P) / ∆ D 
The stiffness of the artery is therefore not only related to the volume of blood 
transported but also intrinsic properties of the arterial wall (Gosling, 2003). The 
latter undergoes physical changes as a result of athero- and arterio-sclerosis, 
two distinct pathological processes, which have the effect of increasing arterial 
stiffness. Ang II causes the proliferation of vascular smooth muscle cells and 




latter is thought to play a significant role, not just in DCT salt handling, but also 
in inducing vascular fibrosis through collagen synthesis and hence arterial 
stiffness (Rehman, 2001).  
 
Pulse Wave Velocity (PWV) has been accepted as the most practical method of 
assessing arterial stiffness and is employed in both research and clinical practice 
(as described in Chapter 4). PWV is based on the principle that stiffer arteries 
transmit the pulsatile components of pressure more rapidly due to decreased 
compliance of the vessel wall (O’ Rourke, 2002). 
 
1.4.4   Increased Wave Reflection: Increased Peripheral and  
Central Systolic BP 
During ventricular contraction, blood leaves the left ventricle, with a defined 
pressure; along the arterial tree as an incident pressure wave (O’Rourke, 2002). 
The arteries in turn produce a reflected wave back to the left ventricle as a 
consequence of their limited distensibility, but also their progressively 
narrowing diameters towards the peripheral vasculature. Reflections were 
thought to occur most prominently at major junctions – e.g. the aortic 
bifurcation, major arterial branching angles etc. but may occur at other sites 
(O’Rourke, 2002). Both the amplitude and the time of arrival of the reflected 
wave on the incident wave affect the resultant pressure wave and hence blood 
pressure. In younger people, the reflected wave arrives back later in the cardiac 
cycle, during ventricular relaxation (diastole) and aids in the perfusion of the 
coronary arteries. With stiffer arteries, the reflected wave superimposes on the 




the initial pressure wave occurs. The resultant pressure that the left ventricle is 
exposed to is called the central systolic pressure (cSBP) and this increases the 
earlier the reflected wave returns. Also, the speed at which this happens relates 
to the PWV and hence to the arterial stiffness. Arteries stiffen with increasing 
age and in hypertensive states (O’Rourke, 1982).  Reflections are also thought 
to cause pressure differences between the “central” SBP measured at the aorta 
(cSBP) and the peripheral systolic pressure (pSBP) measured at the brachial 



















1.5 Predisposing Factors to Salt Sensitive HTN 
 
1.5.1 Factors underlying low renin hypertension and why renin  
is low in black subjects 
Sodium intake 
A low-renin state is associated with “salt-sensitivity”, a pre-disposition towards 
blood pressure increasing with sodium load or decreasing with sodium 
restriction although the concordance of these two conditions may differ 
according to ethnic group (Shimojo, 1995). Greater sodium intake in Black 
versus White people with concurrent suppression of the renin-angiotensin 
system could potentially account for low-renin hypertension in Black people. 
However, although accurate data on sodium intake at a population level are 
limited, sodium intake alone is thought not to account for low-renin 
hypertension. Rather, low-renin hypertension is thought to be due to increased 
renal sodium reabsorption (Lovati, 1999) 
 
Increased sodium retention (genetic influences) 
Several monogenic forms of low-renin hypertension such as Gordon’s 
syndrome, glucocorticoid-remediable aldosteronism and Liddle’s syndrome, all 
of which are characterized by increased renal sodium absorption in the distal 
tubule, suppress renin and lead to salt sensitive hypertension (Shimijo, 1995). 
Additionally, genetic variations in candidate genes impacting these pathways 
have been implicated in both systolic and diastolic hypertension in the Black 




syndrome, these syndromes account for only a small proportion of low-renin 
hypertension, but they suggest that low PRA may be due to a compensatory 
suppression of the RAAS when renal tubular sodium absorption is increased 
due to an effect independent of the RAAS. One author considers that the lower 
PRA in black compared to white subjects does not reflect differences in dietary 
sodium intake but is part of a “corrective” mechanism designed to maintain 
sodium balance in the presence of an increased tendency for sodium retention in 
black people (Sagnella, 2001). A plausible explanation for the higher renal 
tubular sodium reabsorption in black people might be related to mutations of the 
genes encoding the amiloride sensitive sodium channel. In one London study, 
measurement of the Na channel coding T594M gene found significantly higher 
levels of a T594M polymorphism in women, with a significant association with 
hypertension when adjusted for age. The prevalence of the T594M mutation 
was also higher in black people with hypertension than those without (Baker, 
1998). Another possible mechanism relates to diminished activity of the enzyme 
11ß-hydroxysteroid dehydrogenase type-2 enzyme (11ßHSD2). This enzyme 
protects the aldosterone receptor from occupation by cortisol (Lovati, 1999). A 
decreased activity of11ßHSD2 has been reported in white salt sensitive people, 
but the relevance of 11ßHSD2 activity to salt sensitivity in black people (in 
whom salt sensitivity is of greater prevalence) and whether it might explain 








Whilst the above possibilities do not directly involve the RAAS, but rather an 
alternate mechanism that leads to compensatory reduction in PRA and hence the 
RAAS, it is possible that ethnic differences in PRA relate directly to differences 
in activity of the RAAS. Genetic studies have shown ethnic variation in 
restriction fragment length polymorphisms at the gene loci for renin (Barley, 
1991) that could be implicated in lower PRA in black compared to white 
subjects.  Price suggests that low PRA in black compared to white subjects 





















1.6 Summary of Introduction 
 
Hypertension-related cardiovascular disease represents a significant health 
burden globally, especially in minority ethnic groups. The main contributor to 
this greater burden could be the differences observed in both the prevalence and 
type of hypertension observed in different ethnic groups. Salt sensitive 
hypertension and a low-renin salt sensitive status have been shown to be more 
prevalent in the Black subjects and might therefore offer an explanation for the 
higher incidence of hypertension-related CVD in this group. It is also 
appreciated that an additional cardiovascular risk due to reduced availability of 
endothelium-derived NO and impaired endothelial function may contribute to 
CVD morbidity and mortality in Black subjects. NO plays a direct role in 
sodium homeostasis and reduced levels may decreased sodium excretion by the 
nephron. It is possible, therefore, that reduced NO availability may be a 






2. MAIN HYPOTHESES 
 
Subjects of Black African or Black Caribbean ancestry are known to have 
reduced flow mediated dilation (FMD) a measure of nitric oxide (NO) 
availability, compared to White European subjects (Bild, 2002). They are also 
known to have increased sodium retention as reflected by low plasma 
concentrations of renin. NO may influence sodium homeostasis by a natriuretic 
effect to decrease renal tubular sodium reabsorption. Reduced NO availability 
may explain low renin and low FMD in Black African or Caribbean as 
compared to White subjects. My hypotheses are that: 
 
I NO availability, as determined by FMD, relates to renin independently of 
ethnicity and other conventional risk factors for cardiovascular disease 
including age, gender, blood pressure and serum lipids. 
 
II This association is driven by NO availability determining sodium 
homeostasis and renin status so that:   
a) Modulation of sodium load and renin does not influence FMD.    
b) Inhibition of NO synthase inhibits sodium excretion; inhibition of 













I To determine whether NO availability, as determined by FMD, relates to 
renin independently of ethnicity and other confounding factors. 
 
II To determine whether other measures of vascular function relate to renin 
independently of ethnicity and other confounding factors. 
 
III To determine whether this association is driven by NO availability 
determining sodium homeostasis and renin status such that: 
• Modulation of sodium load and renin does not influence FMD 
• Inhibition of NO synthase inhibits sodium excretion; inhibition of 
















1. To perform a cross sectional study to examine the relationship between flow 
mediated dilatation (FMD, a measure of endothelium-derived NO 
availability) in the forearm and plasma renin activity in participants 
representative of the asymptomatic population in the UK, including black 
African, black Caribbean and white European subjects. A secondary 
objective will be to examine the relationship of measures of vascular 
structure (carotid intima-media thickness and pulse wave velocity) to 
ethnicity and plasma renin activity. The relationship between FMD and 
plasma renin activity will be examined using multivariate regression 
analysis incorporating ethnicity and other confounding variables such as age 
and gender, blood pressure and serum lipids. Hypothesis I predicts that 
FMD will relate to renin independent of ethnicity and other confounding 
variables. 
 
2. To examine the influence of oral salt loading on FMD in a subset of low 
renin (< 0.3 ng/ml/hr) subjects selected from the cross-sectional study above. 
A two-phase randomised cross-over study will be performed where subjects 
will receive a low salt diet plus placebo salt load and a low salt diet plus salt 
load in random order. Blood pressure, plasma renin activity, isoprostanes (as 
a marker of oxidative stress) and FMD will be measured after each 
treatment phase of the study. The major outcome will be FMD, which will 
be compared on the low and high salt intakes. Hypothesis II(a) predicts that 





3. To examine the influence of the inhibition of NO synthase, using the NO 
synthase inhibitor L-NMMA, on urinary sodium excretion and whether the 
influence of L-NMMA on urinary sodium excretion differs according to 
plasma renin activity.  The relation between the effect of a fixed dose of L-
NMMA on fractional urinary sodium excretion and plasma renin activity 
will be examined using multivariate regression analysis. Hypothesis II(b) 
predicts that the anti-natriuretic effect of L-NMMA will be positively 




4.   GENERAL METHODS 
 
4.1   Subject Recruitment 
 
The experimental work described in this thesis was approved by the Guy’s and 
St. Thomas’s NHS Foundation Trust (GSTT) Ethics Committee. Participants 
were each assigned a unique code that was used in all databases to avoid 
linkage of personal identifiers to particular volunteers. 
 
Asymptomatic volunteers were recruited using King’s College London internal 
webmail and from other databases within the department of Clinical 
Pharmacology at St. Thomas’ Hospital. Written informed consent was obtained 
from all participants before starting the study protocol. 
 
A telephone-screening questionnaire was carried out to determine the suitability 
of potential participants for inclusion into the study. During the interview, 
suitable participants were asked to avoid strenuous exercise for 24 hours before 
their study visits and to avoid taking caffeine. They were informed of the 
necessity of the overnight fast (from 22:00hrs) to obtain fasting biochemistry 








4.2 Determination of Office BP and 24hr Ambulatory Blood  
Pressure Monitoring (ABPM) 
 
Seated office brachial artery blood pressure was measured in accordance with 
British Hypertension Society guidelines in triplicate using an automated 
oscillometric device (Omron® 705CP, Omron®, Matsusaka, Japan) (El Assad, 
2003). Participants were comfortably seated in a warm, quiet consultation room 
for 30 minutes before the first blood pressure reading was taken. The bladder of 
the cuff was placed 2 – 3 cm above the antecubital fossa with the forearm 
supported to heart level (below this tends to overestimate the systolic BP while 
above this tends to underestimate it). Readings were taken five minutes apart 
and the average of three readings was taken as the seated office BP.  
 
Twenty-four hour ambulatory blood pressure monitoring was perfrormed using 
the Spacelabs® Medical 90217 Ambulatory BP Monitors. This device has been 
validated by both the BHS and JNC VII for the determination of ambulatory 
blood pressure monitoring. Twenty-four hour ambulatory BP monitoring has 
been shown to be a better predictor of cardiovascular risk than the accepted 
office BP measurements. Firstly, it can identify those people who might have a 
unrepresentatively high office BP because of the psychological stress associated 
with the office visit, so called “white coat hypertension”. Secondly, it identifies 
those whose office readings are within the normal reference ranges but who 
may be above limits when carrying out their usual 24-hour routine. The latter is 
often referred to as “masked hypertension”. It also provides values of blood 




prognostic value than day-time blood pressures (Faggard, 2008). The absence of 
the physiologic fall in BP during the night has also been associated with higher 





4.3   Pulse Wave Analysis: Central Systolic Blood Pressure and  
Augmentation Index 
 
Peripheral systolic blood pressure measured in the upper limb in the usual way 
as described above is amplified above central systolic blood pressure (cSBP) in 
the aorta by pulse wave reflection in the upper limb. This amplification depends 
not only on characteristics of the upper limb but the character of the central 
pressure waveform and hence on pressure wave propagation and reflection 
within the systemic circulation.  Differences between peripheral SBP and cSBP 
are typically in the order of 10 mmHg but increase with increasing heart rate 
and/or peripheral vasodilation and may exceed 50 mmHg (Kroker, 1955). cSBP 
may be more closely related to cardiovascular outcomes than pSBP 
(Vlachopoulos, 2010) and anti-hypertensive drugs may have differential effects 
on cSBP and pSBP. In the CAFE study, for example, the intervention producing 
lower cSBP (but similar pSBP) was associated with improved outcome 
(Williams, 2006). cSBP is usually estimated by application of a “generalised 
transfer function” (GTF) applied to a peripheral pressure waveform (Chen, 
1997). This approach has been criticised as dependent on limited and arbitrary 
“training” data from which such GTF are derived since these data may not be 
representative of subjects to which the GTF is ultimately applied (Hope, 1997). 
An alternative approach identifies the pressure at the late systolic shoulder of a 
peripheral pulse (pSBP2, Figure 5) which has empirically been found to 
approximate cSBP (Pauca, 2004; Munir, 2008). An explanation for this has 
been by provided in terms of wave reflection theory by Hughes at al: pSBP2 is a 




(the product of rate of change of pressure and flow) is, therefore, also zero.  The 
intensity of the backward travelling compression wave that causes peripheral 
amplification is then close to zero and peripheral and central systolic pressures 
are equal (Hughes, 2008). This approach has been validated (Guilcher, 2011) 
and is the method used in this thesis.  
 
pSBP2 is also used to derive the peripheral augmentation index (pAI), an index 
which is closely related to central augmentation index (cAI) and is thought to 
quantify pulse wave reflection within the arterial tree (Nichols, 1998; 
Melolenovsky, 2007) AI was thought to be related mainly to the timing of 
pressure wave reflection and therefore to be closely related to aortic pulse wave 
velocity (PWV). However, it is now acknowledged that AI can be changed 
independently of PWV and it is regarded as a composite index of wave 
reflection dependent on peripheral arterial tone and arterial stiffness (Kelly, 
2001). It may also be influenced by ventricular ejection characteristics and its 














Peripheral pressure waveforms may be obtained using a device called the 
Finometer (Finapres Medical Systems). This system has been previously 
validated with the more widely used SphygmoCor system (Millasseau, 2000). A 
finger probe was placed on the index finger of the left hand which is 
approximately10 cm below the level of the heart. Peripheral BP readings were 
taken with the Omron® 705CP and entered into an in-house software 
programme for the analysis of the waveform. Three pulse wave analysis 
readings were taken, each with repeat blood pressure measurements. Records of 



















4.4 Pulse Wave Velocity 
 
Arterial stiffness can be assessed using the velocity of pressure propagation 
along the arterial system (O’Rourke, 2002). A time delay occurs between the 
arrival of the wave impulse to the carotid or brachial artery and that arriving at 
the femoral artery. This time represents the transit time (TT) for the wave 
propagation between these two points. The pulse wave velocity (PWV) between 
these two surface points can therefore be estimated using the formula: 
PWV = L/TT 
where L is the path length between the two sites (e.g. carotid and femoral 
arteries) and can be estimated from surface markings. Pulse wave velocity was 
measured using the Vicorder® device (Skidmore Medical). The device utilises 
two cuffs that are separately applied to the arm and thigh. The pressure in the 
cuffs reaches 65 mmHg on cuff inflation. The distance between the arm and 
thigh cuffs is measured and entered into the programme as L and PWV is 
calculated based on the TT. The acquisition of the measurements using the 
device software is shown as a screen shot in Figure 6.Three values were taken 







































4.5 Flow mediated Dilatation 
 
Flow mediated dilatation was used to assess endothelial function (Davignon, 
2004). Two-dimensional longitudinal images were obtained of the brachial 
artery approximately 5 cm proximal to the antecubital fossa using the Acuson® 
128XP ultrasound scanner equipped with a 7.5 MHz linear array transducer. A 
cuff was placed 3 cm distal to the antecubital fossa and was inflated to 250 
mmHg for 5 minutes. Images were taken at baseline and for five minute after 
cuff release. The images were captured by trigger on the R wave of the 
continuous ECG monitoring representing end diastole. Figure 7 shows a cross 
sectional view of the brachial artery during FMD scanning. Images were 
digitized for subsequent blinded analysis using automated edge detection 
software (Brachial Analyser, Medical Imaging Applications, LCC, Iowa, USA).  
After 10 min, baseline images were again repeated for one minute and 
endothelium-independent vasodilatation was assessed by administering 25 µg of 
GTN sublingually. Dilation to NTG (NTGD) was expressed as the percentage 
increase in brachial artery diameter from baseline to the maximal dilation after 
NTG. 
 
FMD was calculated as below: 




































4.6 Carotid Intimal Media Thickness (CIMT) 
 
High-resolution ultrasound (Siemens CV70) was used to obtain images of the 
common carotid artery. Mean common carotid intima-media thickness (CIMT) 
was assessed from digitized images obtained in diastole of the near and far 
walls of both common carotid arteries 1-2 cm proximal to the flow divider 
(Mancini, 2004; Bots, 1997). This method is recognized as one of the most 
robust measures of IMT since the reproducibility of common carotid IMT 
measurements is higher than that of other segments, and in most studies to date 
additional measurements from the bifurcation and internal carotid has not 
improved the predictive value of IMT (O’Leary, 1999). The presence of plaque 
(defined as a focal widening relative to adjacent segments with protrusion into 
the lumen) within the near and far walls of the common carotid, bifurcation and 
internal carotid of both right and left arteries was scored according to the total 
number of plaques (giving a score of 0-12) (Sorke, 2004). Figure 8 shows 














4.7 Biochemical Assays 
 
Plasma renin activity (PRA) and aldosterone were measured at St Mary’s 
Hospital, London. PRA was determined using a modification of the method 
described by Menard et al., a radio-immunoassay being used to measure 
angiotensin I generated from plasma incubated with endogenous plasma 
angiotensinogen substrate (Menard, 1972). The coefficient of variation (CV) for 
between-batch samples using this assay was 10.2% at a mean level of 1.26 
ngml-1hr-1 with a lower limit of detection of 0.25 ngml-1hr-1. The distribution of 
plasma renin activity was skewed, with some values below the limit of 
detection. These values were set equal to the lower limit of detection. A radio-
immunoassay was also used to measure plasma concentrations of aldosterone. 
The CV for between batch samples was 7.5% at a mean level of 22.2 ng/dl and 
the lower limit of detection 2.5 ng/dl. All other biochemistry assays were 
measured in Guy’s and St Thomas’ Hospital Chemical Pathology Laboratory 













4.8 Statistical Analysis and Sample Size calculations 
 
Subject characteristics are summarised as means (standard deviation, SD) or as 
medians (inter quartile range) for non-normally distributed variables. 
Differences between ethnic groups were tested using a Student’s t-test or Mann-
Whitney test for non-normally distributed variables and Chi-squared test for 
categorical values. Results are summarised as means ± standard error (SE). 
Associations between FMD (and other measures of vascular function), ethnicity 
and renin were examined using univariate and multivariate regression analysis 
with ethnicity (black or white) coded as a dummy variable. The influence of 
altering dietary salt intake on FMD was examined using analysis of variance for 
repeated measures (ANOVA). The influence of NO synthase inhibition on 
sodium excretion was examined using a paired Student’s t-test. The relation of 
the amount of inhibition of sodium excretion produced by NO synthase 
inhibition to ethnicity and renin status was examined using multiple regression 
analysis. All analysis was done with SPSS version 19. 
 
Sample size calculations 
For the cross-sectional study comparing vascular measures across ethnic groups, 
a total sample size of 120 was estimated to give 90% power (with P<0.05) to 
detect an effect of ethnicity or of plasma renin activity accounting for > 10% of 
the variance in the vascular measures when adjusting for age, sex, blood 
pressure and sodium intake. The sample size was calculated for hierarchical 
multiple regression assuming the addition of one variable accounting for > 10% 




An a-priori Sample Size Calculator for Hierarchical Multiple Regression 
Analysis was used. This software is now available in a web-based version from: 
http://www.danielsoper.com/statcalc (Soper, 2014) 
 
In the salt intervention study, a sample size of 20 was estimated to allow a 
difference in FMD of > 2% points with > 90% power to be detected between 
low and high salt intakes. This calculation was for a paired t-test assuming a 
within-subject standard deviation of 2% points in FMD. 
 
In the NO synthase inhibition study, a sample size of 40 was estimated to give 
90% power to detect an effect of plasma renin activity accounting for > 20% of 
the variance in the fractional excretion of sodium when adjusting for baseline 














5. CROSS SECTIONAL STUDY 
 
5.1   Background 
 
Previous studies examining ethnic differences in renin status have mainly 
focused on hypertensive subjects, although studies in normotensive subjects do 
suggest that PRA is lower in normotensive as well as hypertensive black 
compared to white subjects (James, 1986;  He, 1999). Similarly studies on 
ethnic differences in vascular characteristics have focused mainly on patients 
with hypertension or older subjects with risk factors for vascular disease. The 
aim of this study was to examine ethnic differences in salt intake, renin status 
and vascular structure and function in an apparently asymptomatic group of 
young adults of African/African-Caribbean and White ethnicity recruited from 
educational establishments in South London. Because of the possible relation 
between NO and sodium homeostasis discussed in Chapter 1, a specific aim 
was to examine the relationship between flow-mediated dilation (this being 











5.2 Participant Characteristics 
 
Participants for this study were recruited using an advertisement on King’s 
College London internal webmail and from databases in the Department of 
Clinical Pharmacology, St. Thomas’ Hospital; participants were mainly staff or 
students of the college and other educational establishments. The advertisement 
made clear the rationale for the study and the requirement for inclusion of 
persons of African/African-Caribbean ethnicity aged between 18 and 50 years.  
Towards the end of the study, these inclusion/exclusion criteria were relaxed to 
allow the inclusion of subjects up to age 60 in order to achieve the required 
recruitment numbers. The response to this resulted in an approximately 
balanced recruitment of persons of African, African-Caribbean and Caucasian 
self-defined ethnicity. Exclusion criteria included: BMI > 35 kg m-2; smoking 
within the last 9 months; diagnosis of diabetes mellitus, hypertension, 
cardiovascular disease, sickle cell disease (but not sickle cell trait) or any other 
significant condition; alcohol consumption more than 14 units/week for women 
and 21/week for men in keeping with the current National Health Service 
(NHS) UK recommendations. Subjects with undiagnosed hypertension found to 
be hypertensive in this study were not excluded but were referred to their 








5.3   Study Protocol 
 
Participants were seen in the research facility on two consecutive study days. 
All participants received a reminder telephone call the evening before the first 
visit to remind them to fast overnight as well as the necessity for a 24-hour 
urine collection the following day. Participants arrived on the morning of the 
first day having completed an overnight (at least 12 hours) fast. Seated blood 
pressure measurements were then taken using an Omron® device after at least 
thirty minutes with the participant seated and this was repeated at five minute 
intervals for two more readings. The average of these three readings was used 
as the resting clinic blood pressure. Anthropometric measures: height, weight 
and waist and hip circumferences were recorded and BMI and waist to hip ratio 
calculated. Participants were asked to lie supine for a further ten minutes before 
the first supine reading of blood pressure was taken. Measurements were then 
taken of pulse wave velocity with the Vicorder® device; with appropriate cuffs 
placed on the right arm and thigh. Care was taken to ensure that the thigh cuff 
was applied as high up the thigh as possible with the participant’s knee initially 
slightly bent. Three readings were then taken five minutes apart and an average 
reading was taken as the pulse wave velocity. With participants still supine, the 
Omron® blood pressure cuff was then applied to the left arm and the 
Finometer® finger probe was applied to the right index finger for the 
measurement of pulse wave analysis. Three consecutive readings were then 






Ultrasound measurements of flow mediated dilation (FMD) and carotid intimal 
media thickness (CIMT) were obtained using the Siemens CV70. Images were 
digitalized for subsequent blinded analysis using automated edge detection 
software (Brachial Analyser, Medical Imaging Applications, LCC, Iowa, USA). 
CIMT measurements were taken first beginning with the left carotid artery in 
transverse section. For measurement of FMD, the participant’s left arm was 
suitably positioned and a BP cuff was applied to the forearm just below the 
medial epicondyle. The ultrasound probe was then positioned over the brachial 
artery about 5 cm above the elbow. A baseline scan was the taken for one 
minute with image storage for future analysis and printed copies taken for 
participant’s printed records. The cuff was then inflated to a pressure of 250 
mmHg while still scanning the brachial artery. This was left inflated for 5 
minutes while still scanning the brachial artery. The cuff was then deflated and 
images were stored at 5, 10, 15 and 30 seconds with continuous scanning for 
another 5 minutes.  
 
A further scan was taken at baseline for one minute followed by the sublingual 
administration of 25 mcg of glyceryl trinitrate (GTN). This was immediately 
followed by 5 minutes of further scanning. FMD was expressed as the 
percentage increase in brachial/radial artery diameter from baseline to maximal 
dilation that occurred 30 to 90 sec after the release of the cuff.  Dilation to GTN  
(GTND) was expressed as the percentage increase in brachial artery diameter 





With patients remaining supine, venous blood was taken for the measurement of 
plasma glucose, electrolytes, creatinine, total-, LDL- and HDL-cholesterol, 
triglycerides, plasma renin activity and serum aldosterone measurement. 
Samples of serum and plasma were also stored at -80 C.  
 
Participants were then given containers for the collection of a 24-hour urine 
collection and fitted with a twenty-four hour ambulatory blood pressure monitor 
(24h ABPM). Participants then left and returned the following day at the same 
time of day, having performed a 24h urine collection and having undergone the 
24h AMBP. The total volume of urine was measured and a sample stored at – 
80oC for future analysis. A sample was also sent to the clinical chemistry 
laboratory for the measurement of urinary sodium, potassium and creatinine 
concentrations. Twenty-four hour urinary sodium was then calculated from 
















5.4    Results 
 
5.4.1  Baseline Participant Characteristics 
A total of 144 participants were enrolled in this cross sectional study. One 
participant withdrew due to unexpected relocation overseas, thus 143 
participants completed the study. Eighty-four (59%) were black and of these 
65% (55) were African while 35% (29) were of Black Caribbean ancestry. The 
remainder of the participants (59) was of white European ethnicity. Two black 
subjects and 5 white subjects were aged over 50. 
Table 1 shows the characteristics of the participants categorized by ethnicity 
(described as black or white). There was no significant difference in the mean 
age or waist: hip ratio in the two groups but black participants had significantly 
greater BMI compared to white participants. There were no statistically 
significant differences in either systolic or diastolic blood pressures recorded on 
the clinic visit. There was, however, a statistically significant difference in the 
daytime systolic BP with higher day-time systolic BP in black compared to 
white participants (P<0.004) but no significant difference in night-time systolic 
BP or in day or night diastolic BP (table 1). There were no significant 
differences in serum lipids between the two ethnic groups.  Fasting plasma 
glucose was marginally but significantly higher in black compared to white 






Table 1: Baseline Participant Characteristics in Cross-Sectional Study 
Measure ALL Black White P value 
n 143 84  59   
Age (years) 30 (10) 31 (10) 30 (10)  NS 
BMI (Kgm-2) 25.7 (4.5) 26.8 (4.5) 24.2 (4.0) < 0.0001 
Waist: Hip 0.79 (0.14) 0.80 (0.11) 0.79 (0.17) NS 
BP (mmHg) 









Seated Diastolic BP 76 (9) 76 (9) 76 (9) NS 
ABPM Systolic (day) 122 (12) 125 (13) 119  (9) 0.004 
ABPM Diastolic (day) 74 (8) 75 (8) 74 (8) NS 
ABPM Systolic (night) 115 (11) 117 (12) 112 (9) NS 
ABPM Diastolic (night) 67 (7) 68 (8) 67 (6) NS 
Total Chol. (mmol/L) 4.52 (0.99) 4.54 (1.00) 4.48 (0.96) NS 
LDL (mmol/L) 2.60 (0.88) 2.65 (0.91) 2.52 (0.83) NS 
HDL (mmol/L) 1.56 (0.43) 1.55 (0.40) 1.57 (0.49) NS 
TAG (mmol/L) 0.80 (0.49) 0.75 (0.43) 0.87 (0.45) NS 
Glucose (mmol/L) 4.6 (1.4) 4.6 (1.0) 4.8 (1.0) < 0.05 
Serum Na (mmol/L) 142 (2) 142 (2) 143 (2) NS 
Serum K (mmol/L) 4.1 (0.3) 4.2 (0.3) 4.1 (0.3) NS 
Urea (mmol/L) 4.7 (1.4) 4.6 (1.3) 4.7 (1.7) NS 
Creatinine (mmol/L) 80 (15) 84 (16) 75 (12) 0.001 
PRA (ngml-1hr-1)1 0.71 (0.6) 0.6 (0.6) 0.9 (0.6) 0.0142 
Aldosterone (pmol/L) 176 (108) 171 (102) 185 (112) NS 
Urine Na: Cr 9.2 (3.9) 9.2 (3.3) 9.3 (4.7) NS 
 
Values are means (SD) except where noted. P values refer to differences between black 
and white subjects (unpaired t-test except where noted). BMI, body mass index; 
ABPM, ambulatory blood pressure; HDL, high density lipoprotein; LDL, low density 
lipoprotein; TAG, triacylglycerol; Na, sodium; K, potassium; PRA, plasma renin 
activity; Urine Na:Cr, ratio of urine sodium:creatinine concentrations. 




Urinary Sodium excretion and Plasma Renin Activity in relation to 
ethnicity 
24-hour urinary sodium/creatinine was similar in the two ethnic groups but 
PRA was significantly lower in black compared to white participants (P= 0.014, 
by Mann-Whitney U test, Figure 9). When defined as PRA <0.3ng/ml/hr, 54% 
of black participants had a low renin status as compared to 6% of white 
participants (P<0.001). PRA was significantly correlated with age (R=-0.426, P 
< 0.001, Figure 10) but there was no significant correlation between PRA and 
24-hour urinary sodium to creatinine ratio (Figure 11) or to 24 hour urinary 
sodium excretion (P=0.68). When adjusted for age and urinary 
sodium/creatinine, PRA (log-transformed to achieve a normal distribution) was 



















Figure 9: Box plot showing the distribution of PRA in the two ethnic groups. (n=84 
and n=59 for black and white subjects respectively). The median values are shown 
(solid central horizontal lines) with the box marked by the first and third quartiles. The 













































Figure 10: Scatter plot of PRA (log to base 10, Lg10PRA) versus age with subjects 
sub-divided by ethnicity (n=84 and n=59 for black and white subjects respectively).  






























Figure 11: Scatter plot showing lack of relationship between urinary salt excretion as 
urinary sodium to creatinine concentration (Na:Creat) and PRA (log to base 10, 
Lg10PRA, with subjects sub-divided by ethnicity (n=84 and n=59 for black and white 








Vascular measures in relation to ethnicity 
Measures of vascular structure and function for the two ethnic groups are shown 
in Table 2. There was a trend towards lower values of FMD (Figure 12) and 
higher values of PWV in black compared to white participants but this did not 
reach significance. AIx and GTND were not significantly different in the two 
groups. CIMT was, however, significantly greater in black compared to white 
participants. These findings were unchanged when adjusted for age, gender, 
blood pressure and other subject characteristics found to be significantly 
correlated with the vascular measures. 
 
Table 2: Summary of means for vascular outcome measures according to ethnicity. 
Measure Black White  
 (n=84) (n=59) P value 
PWV (m/s) 10.1 (1.8)  9.9 (1.3) NS 
AI (%)  55.5(18.5)  53.8 (20.4) NS 
FMD (%)  5.9 (3.6)  6.8 (4.1) NS 
GTND (%)  9.8 (5.2)  10.1 (5.1) NS 
Average CIMT (mm) 0.48 (0.12)  0.44 (0.11) < 0.005 
 
Values are means (SD). P values refer to differences between black and white subjects. 
PWV, Pulse Wave Velocity;  AI, Augmentation Index;  FMD, Flow Mediated 




















Figure 12: Box plot of FMD in black and white ethnic groups (n=84 and n=59 for 
black and white subjects respectively.  The median values are represented as the bold 
horizontal line in each box with the 1st and 3rd interquartile ranges shown as the lower 
and upper borders respectively. The extension lines show the range of values for each 




















Relation of vascular measures to participant characteristics and PRA  
Results of univariate regression analysis examining the relation of each of the 
vascular measures to participant characteristics are shown in Table 3. FMD was 
weakly but significantly negatively correlated with night ambulatory systolic 
BP and strongly positively correlated with PRA (Figure 13). CIMT was 
significantly correlated with age, ethnicity, central SBP, daytime ambulatory 
SBP, HDL-cholesterol and PRA. PWV was significantly correlated with age, 
BMI, all BP components, LDL-cholesterol and negatively correlated with PRA. 
AIx was significantly correlated with age, male gender, central SBP, 





















Figure 13: Scatter plot of FMD vs PRA (log to base 10, Lg10 PRA) with subjects sub-
divided by ethnicity (n=84 and n=59 for black and white subjects respectively). The 


















Multiple regression (stepwise backward) analysis demonstrated that FMD was 
significantly independently correlated only with PRA in a model where age, 
gender, ethnicity, 24-hour urinary sodium and ambulatory night systolic blood 
pressure (the only variable significantly associated on univariate analysis with 
FMD apart from PRA) were entered. 24 hour urinary sodium was used in 
preference to sodium/creatinine ration because of the possibility of confounding 
due to differing lean body mass in black and white subjects. However, FMD 
remained significantly independently positively associated with PRA when 
either 24 hour urinary sodium: creatinine or 24 hour urinary sodium was forced 
into the model and irrespective of whether any or all of gender, age and 
ethnicity were forced into the model. CIMT was significantly independently 
correlated with age, ethnicity and central SBP. PWV was significantly 
independently correlated with age, BMI, night ambulatory SBP and central 
SBP. AIx was significantly independently correlated with age, gender, central 






Table 3: Univariate regression analysis of FMD and CIMT versus age, gender, 
ethnicity and other subject characteristics significantly correlated with FMD and CIMT.  
 
Dependent variable Independent variable R P 
FMD Age -0.05 =0.14 
 Gender 0.08 =0.135 
 Ethnicity 0.11 =0.18 
 ASBP (night) -0.17 <0.05 
 PRA 0.20 <0.001 
    
CIMT Age 0.36 <0.001 
 Gender 0.05 =0.57 
 Ethnicity 0.21 <0.01 
 cSBP 0.39 <0.001 
 ASBP (day) 0.17 <0.05 
 HDL 0.18 <0.05 
 PRA 0.30 <0.001 
 
R, Pearson’s correlation coefficient;  BMI, body mass index;  cSBP, central systolic 
blood pressure;  PRA, plasma renin activity;  ASBP, ambulatory systolic blood 








Table 4: Univariate regression analysis of PWV and AIx versus age, gender, ethnicity 
and other subject characteristics significantly correlated with PWV and AIx.  
 
Dependent variable Independent variable R P 
PWV Age 0.42 <0.001 
 Gender 0.06 =0.47 
 Ethnicity -0.06 =0.50 
 BMI 0.32 <0.001 
 Waist:hip 0.20 <0.05 
 cSBP 0.52 <0.001 
 ASBP (day) 0.32 <0.001 
 ADBP (day) 0.38 <0.001 
 ASBP (night) 0.31 <0.001 
 ADBP (night) 0.28 <0.001 
 LDL 0.17 <0.05 
 PRA -0.29 <0.001 
    
AIx Age 0.63 <0.001 
 Gender 0.35 <0.001 
 Ethnicity -0.04 =0.60 
 HR -0.30 <0.001 
 cSBP 0.80 <0.001 
 ADBP (day) 0.35 <0.001 
 LDL 0.35 <0.001 
 PRA -0.36 <0.001 
 
R, Pearson’s correlation coefficient;  BMI, body mass index;  cSBP, central systolic 
blood pressure;  PRA, plasma renin activity;  ASBP, ambulatory systolic blood 









Table 5: Multivariate regression analysis of FMD, CIMT, PWV and AIx versus 





variable(s) β  P 
FMD PRA -0.28 <0.001 
    
CIMT Age 0.27 <0.001 
 Ethnicity 0.21 <0.01 
 cSBP 0.27 <0.02 
    
PWV Age 0.24 <0.01 
 BMI 0.15 <0.05 
 ASBP (night) 0.24 <0.01 
 cSBP 0.27 <0.01 
    
AIx Age 0.19 <0.01 
 Gender 0.20 <0.001 
 HR -0.16 <0.01 
 cSBP 0.60 <0.001 
 
b, standardized regression coefficient; BMI, body mass index;  cSBP, central systolic 
blood pressure; PRA, plasma renin activity;  ASBP, ambulatory systolic blood 






Ethnic differences in Plasma renin activity 
 
As described in the introduction, it is well appreciated that there are ethnic 
differences in renin status in hypertensive subjects, with a greater prevalence of 
low PRA in black compared to white subjects. Less is known about renin status 
in normotensive subjects. However, the findings of this study confirm findings 
in other population studies (Sagnella, 2001) that, even in predominantly 
normotensive subjects, PRA activity is lower in black compared to white 
subjects and hence the prevalence of “low renin” status is greater in black 
compared to white subjects. Suppressed PRA activity could be due to increased 
salt intake (He, 2001) and/or increased renal sodium reabsorption. There are 
difficulties in estimating salt intake since 24 urinary collections may be 
incomplete and attempting to normalize this by using a sodium: creatinine ratio 
may be confounded by ethnic differences in lean body mass. However, there 
was no significant correlation of PRA with either measure of urinary sodium 
excretion. The lack of correlation between PRA and urinary sodium does not 
mean that dietary sodium does not influence PRA, since a dietary intervention 
in which there is a large change in salt intake does influence PRA as will be 
demonstrated in Chapter 6. However, lack of a correlation of PRA with urinary 
sodium in the present study, in which the range of salt intake was restricted to 
that due to usual variation in dietary intake, is consistent with the established 
view that ethnic differences in renin status relate primarily to renal sodium 
handling rather than salt intake (Bochud, 2009). It is notable that in this 
predominantly normotensive group ambulatory daytime systolic blood pressure 







Ethnic differences in vascular structure and function: FMD 
 
There is relatively little data on ethnic differences in FMD from previous 
studies, which have been limited to small sample sizes and/or included patient 
populations. One study compared FMD in 28 young asymptomatic black 
African-Americans and 24 white Caucasian subjects and demonstrated lower 
FMD in black compared to white subjects (1.76 ± 0.56% in black compared to 
8.79 ± 1.22% in whites subjects, P<0.001) (Perregaux, 2000). Similarly 
Melikan et al demonstrated lower FMD in a group of 30 young black African 
men compared to that in a group of 28 white European men in the UK, although 
the difference (5.2 ± 0.3 vs 6.3 ± 0.4 % in African vs. white European) was less 
marked than in the study by Perragaux et al (Melikan, 2007). By contrast, in a 
larger group of 228 black and white Americans, approximately 50% of whom 
were hypertensive, Gokce et al demonstrated no difference in FMD between 
black and white subjects (Gokce, 2001). However, in this study, conduit artery 
vasodilation to GTN was enhanced in black compared to white subjects. In the 
study described in this chapter, in a larger sample size than that for previous 
studies in asymptomatic subjects, I found a non-significant trend towards lower 
FMD in young black African and African-Caribbean subjects compared to 
white subjects. Thus the available evidence suggests the FMD is similar or 
reduced in black compared to white subjects, with the possibility that differing 
findings in studies to date relate to the characteristics of the subject groups and 
limitations of self-defined ethnicity in capturing the genetic and environmental 




Ethnic differences in vascular structure and function: 
CIMT 
By contrast to FMD, CIMT represents a structural change in the wall of the 
artery that may represent hypertrophy of vascular smooth muscle in response to 
vascular risk factors, particularly hypertension, and/or early change in the 
intima associated with sub-clinical atherosclerosis. In a population study of 
middle aged subjects in South London, Mackinnon et al found greater CIMT 
but interestingly lower prevalence of carotid plaque in black compared to white 
subjects (Mackinnon, 2010). Whincup et al have reported greater CIMT in 
children of black African compared to those of white European origin 
(Whincup, 2012). The findings of my study are in agreement with these 
previous studies with significantly higher CIMT in young black 
African/African-Caribbean subjects compared to white subjects in South 
London. The probability of atherosclerosis is low in the relatively young 
subjects in my study and in the children studied by Whincup et al. This and the 
presence of higher CIMT but lower risk of sub-clinical atherosclerosis as 
determined by focal protrusion of plaque into the vascular lumen in black 
compared to white subjects in the study of Mackinnon et al suggests that higher 
CIMT in black compared to white subjects is likely to be due to relative 
hypertrophy of vascular smooth muscle rather than thickening of the intima as a 








Ethnic differences in vascular structure and function: AIx 
and PWV 
Arterial stiffness as measured by PWV is another measure of arterial structure. 
Although it has been regarded as influenced by vascular risk factors and 
atherosclerotic change in the arterial wall, it is becoming evident that PWV is 
largely independent of vascular risk factors other than age and blood pressure. It 
is likely that it depends on properties of the elastin and collagen in the 
extracellular material of the arterial wall (London, 2005). AIx is thought to be a 
composite measure of arterial stiffness and pressure wave reflection, being 
influenced by vascular smooth muscle tone as well as arterial stiffness. Previous 
studies in older subjects than in my study have shown either similar (Rezai, 
2011) or increased PWV in black African/African-Carribean subjects compared 
to white subjects (Chaturvedi, 2003). In the present study, however, we 
observed no significant difference in PWV or AIx between young black and 
white subjects. It is possible that higher values of PWV in black subjects in the 
study by Chaturvedi et al were due to higher blood pressures sustained over 
many years since, although differences persisted after adjustment for blood 
pressure at the time of the study, they were not adjusted for long-term blood 















Relationship of FMD to plasma renin activity 
 
 
The relationship between vascular outcome measures and subject characteristics 
in this study shows a novel finding, that FMD is strongly and independently 
associated with PRA irrespective of ethnicity. This finding could help reconcile 
a number of apparently contradictory findings with respect to endothelium-
dependent vasomotor function in hypertensive states whereby endothelial 
function has been variously reported as preserved or impaired. Renin status has 
not been reported in such studies and endothelial function may be depressed in 
low-renin hypertensive states but not necessarily in other hypertensive states. 
That FMD relates more strongly to renin status than to ethnicity suggests that 
the varying results of studies on ethnic differences in FMD may be explained by 
varying renin status of the different ethnic groups. In future studies of FMD and 
ethnicity, the role of renin needs to be explored.  
 
This cross sectional study does not allow us to make any conclusions regarding 
causality of the relation between FMD and PRA. It is possible that sodium 
retention leads to an impairment of availability of endothelium-derived NO or 
alternatively that NO influences sodium retention. These possibilities will be 
examined through modulation of salt intake and Chapter 6 and inhibition of NO 








 It is also important to note that the conclusions can only be generalized 
to subjects with similar characteristics to those in the study population. Our 
study was limited to asymptomatic subjects with no known medical history and 
on no regular medication (i.e. typical of asymptomatic subjects in the general 
population). Inevitably, given the high prevalence of hypertension in the general 
population, a minority of subjects may have had undiagnosed hypertension and 
in future studies it will be important to determine to what extent the presence or 
absence of hypertension may influence the findings. Many subjects were 
overweight and again further studies will be required to determine if the present 


















6.1  Introduction 
 
 
The cross sectional study presented in Chapter 5 demonstrated a significant 
independent positive correlation between FMD and PRA. Salt intake and/or 
sodium retention is thought to be one of the main mechanisms influencing 
vascular smooth muscle tone. A trans-membrane ion channel, Na+ - Ca+, is 
thought to play a major role of regulating the latter in these salt sensitive (low 
renin) subjects. This channel functions in two states, dependent on its polarity, 
and these are as Na+ - Ca+ influx (NCX1) and efflux channels. A high level of 
cytosolic calcium causes smooth muscle contraction and vascular constriction – 
a key factor in the genesis of hypertension. With the use selective inhibitors for 
NCX1, such as SEA4000, this channel has been found to play a role in the 
development of hypertension (Blaustein, 2009).  
 
Subjects with low renin, thought to retain sodium through renal tubular 
mechanisms as discussed in Chapter 1, are described as “salt sensitive”. This 
relates to the influence of salt intake on increasing blood pressure when 
compared with those with higher renin. This has been attributed to the influence 
of sodium on the peripheral arteriolar tone and hence systemic peripheral 
resistance. The extent, to which similar mechanisms could influence endothelial 
function, in particular NO bioavailability, is unclear.  However, it has been 




with resultant inactivation of NO by free radicals such as superoxide anion 
(Kitiyakara, 2003).  
 
The purpose of the study described in this chapter was to examine whether 
modulation of salt intake, and hence PRA, influences FMD as a measure of 
NO-dependent endothelial function. Because of the greater salt sensitivity with 
respect to blood pressure of subjects with low renin, we selected subjects with 
low PRA and examined effects of a low and high salt intake in a crossover 
study design. We also examined the influence of modulating salt intake on 






















• To examine the acute effects of salt loading on vascular function in a 
low renin salt sensitive cohort. 
• To determine the effects of acute salt loading on oxidative stress in a 










































6.3 Recruitment and Participant Characteristics 
 
 
Twenty-one “low renin” (11 men, 10 women) of the participants who took part 
in the cross-sectional study described in Chapter 5 were enrolled in the study. 
Inclusion criteria were identical to the cross-sectional study but additionally 
included a baseline PRA < 0.3 ng/ml/hr as measured in this previous study. The 
value of < 0.3 ng/ml/hr was chosen as a threshold as used by other investigators 
(He, 2002; Duffy, 2005) and it corresponded approximately to the 10th 
percentile in the previous study (for subjects of all ethnicities). Because in the 
previous study, FMD was found to associate with PRA but not with ethnicity, 
PRA was the inclusion criteria rather than ethnicity and both black and white 
subjects were recruited. Subjects were consented separately for this arm of the 
study after full disclosure of information both in a telephone interview and after 
receiving a participant information sheet. Subjects further underwent a dietary 
consultation visit during which their regular diet was reviewed in consultation 
with a dietician and they were counseled on the necessary dietary changes 
required for the study. In addition, we measured oxidative stress by Liquid 
Chromatography – Mass Spectroscopy (LC-MS) for urinary isoprotanes. 
Urinary isoprostanes have been used in previous studies as a marker of 











Following the initial dietary consultation, subjects completed a dietary 
questionnaire and 3 day salt diaries to ascertain the usual sodium intake as 
determined by “sodium points”. Participants were then given dietary advice to 
reduce their sodium content to less than 100 points (2.0g of NaCl equivalent) 
per day. Adherence to this low salt diet was checked through follow-up phone 
calls made on at least 4 occasions throughout the study period and by 24-hour 
collections of urine. Twenty-four hour ambulatory blood pressure monitoring 
and a 24-hour urine collection were arranged on the day before the start of the 
study. Participants then returned between 08:00hr and 08:30hr after an 
overnight fast. Venesection was performed for the measurement of serum lipids, 
sodium, potassium, urea and creatinine. Vascular measurements for pulse wave 
analysis (PWA), pulse wave velocity (PWV) and flow mediated dilation (FMD) 
were recorded as for the cross sectional study. Subjects then entered a 
randomized 2-phase cross-over study design as shown in Figure 16 where they 
received 200 mmol of NaCl (as 20 x 10 mmol NaCl tablets) in one treatment 
phase and matching placebo tablets in the other phase, each phase for 14 days. 
Ambulatory blood pressure was measured and a 24-hour urine collection 
performed on day 12. On day 14, subjects returned again at 08:00hr and 
underwent venesection for serum electrolytes, plasma glucose, PRA and plasma 
aldosterone and measurement of FMD, PWA and PWV. Blood and urine 
biochemistry including PRA and aldosterone were measured in a standardized 

























3-d food diary 
24h ABP 
24h urine collection 
(volume, Na, K, 
creatinine, protein) 
3 x Clinic visits – measurements of arterial function (PWV, PWA, CIMT(1st Clinical visits 
only), FMD)+ blood sample (8-isoprostane F2α, NOx, lipids, glucose, creatinine, urea, Na, 
K, PRA, aldosterone 
2 treatments: 
Background low salt diet 
1) Slow release NaCl 
2) Placebo 
2 x 24h diet recall 
Dietary & 
lifestyle advice 
Treatment 1 Treatment 2 
Day 0 14 28 27 26 13 12 
2 x 24h diet recall 
24h ABP 




24h urine collection 
Standardised 
advice  





6.5   Results 
 
 
The results of the salt intervention study are shown in Table 6. All 21 
participants enrolled completed the study and these included 16 black and 5 
white participants. Table 6 shows the baseline characteristics of the subjects. 
Despite subjects being selected on the basis of PRA  < 0.3 ng.ml-1hr-1 in the 






Table 6: Baseline characteristics of volunteers (n=21) in salt loading study 
 
 
Characteristic Mean SD 
 

















                    





                    











               














































BMI, body mass index; BP, blood pressure; Sys, systolic; Dias, diastolic; HR, heart 
rate; ABPM, ambulatory blood pressure monitoring; Na, sodium; K, potassium; Lg 
PRA, log (base 10) plasma renin activity; Urinary Na:CR, urinary sodium to creatinine 







Table 7: Blood pressure, vascular function and biochemistry on low (placebo) and 
high (NaCl) sodium diets 
 
Measure Placebo Salt  
 Mean SD Mean SD P value  
ABPM Systolic    (mmHg)  124 12 133 16 0.023  
ABPM Diastolic (mmHg)  75 9 82 13 0.106  
PWV (ms-1)  10.0 2.1 10.6 2.3 0.175  
AIx (%)  53.9 22.0 61.4 17.8 0.286  
FMD (%)  5.6 4.0 6.3 4.1 0.613       
 U Na:Creatinine 6.8 3.1 18.8 7.5 0.010  
PRA   (ngml-1hr-1 ) *  0.9 [0.6, 1.4] 0.3 [0.2. 0.95] <0.001  
Urinary 2,3 Dinor 8-IsoF2α (nM) /  
Creatinine (mM)  
6.387 2.976 6.082 3.204 0.556  
Urinary8-Iso-PGF2α (nM) /  
Creatinine (mM)  
0.687 0.341 0.673 0.423 0.657  
 
ABPM, ambulatory blood pressure monitoring; PWV, pulse wave velocity; AIx, 
augmentation index; FMD, flow mediated dilation; U Na:Creatinine, urinary sodium to 
creatinine ratio; PRA, plasma renin activity. 
 
 






Table 7 shows that there was an approximately 3-fold increase in urinary 
sodium excretion, as assessed by the 24-hour urinary sodium/creatinine 
excretion after salt loading on the background of the low salt diet. Salt loading 
led to a reduction in PRA and to an increase in 24-hour ambulatory systolic 
blood pressure (124 mmHg at baseline on the low salt diet vs. 133 mmHg after 
salt loading, P = 0.023). However, there was no significant difference in FMD, 
AIx or PWV after salt loading.  There were no significant interactions between 










































The results suggest that short-term oral salt loading reduces PRA. There was 
also a predicted increase in the systolic blood pressure response on 24 hour 
monitoring. There was no significant difference in measures of arterial stiffness 
or flow-mediated dilatation. This suggests short-term salt loading may cause 
























This sub-study examined vascular and biochemical parameter changes after 
short-term salt loading. A clear difference between sodium excretion was 
demonstrated in the placebo versus salt phases of the study. There was a 
concomitant fall in PRA on salt loading as demonstrated in previous studies for 
both oral and intravenous salt loading and there was a difference of 9 mmHg in 
ambulatory systolic BP between the high and low salt phases of the study. In 
the 2011 Cochrane review by Graudal et al looking at the effects of oral salt on 
blood pressure in 62 trials, they noted a fall of 1.27 mmHg in normotensive 
Caucasians on salt restricted diets (Graudal, 2012). Lack of a change in diastolic 
BP is consistent with observations in the Graudal review with meta-analysis 
showing no significant difference in DBP. This review further supported a 
greater fall in SBP (-4.02 mmHg [95%CI – 7.37, -0.68 mmHg]) in black 
compared to white subjects in a sub meta- analysis including 6 trials with black 
participants. The relatively large change in SBP in our study might reflect the 
high proportion of black versus white subjects enrolled. 
 
This study did not demonstrate a significant change in FMD on acute salt 
loading or restriction. Dickinson et al 2011 showed in a study of a high salt 
meal (HSM) 65 mmol Na compared to low salt meal (LSM) 5 mmol Na, a 
significant difference in FMD between the two interventions (3.39% +/-2.44% 
after HSM versus 6.05% +/- 3.21% after LSM) as early as 30 minutes after the 
intervention (Dickinson, 2011). The renin status in this study, however, was not 




by both a type 2 error and the renin status of the participants in our study with a 
relatively high percentage of low renin subjects. The low renin state might 
reflect chronic changes to the endothelium either directly from Na or another 
mediator such as oxidative stress. These would likely not be reversible on acute 
sodium concentration changes in the vascular compartments.  
 
 
Our study had a number of limitations: 1) the small sample size which makes it 
difficult to exclude a type 2 error. 2) despite subjects being selected on the basis 
of PRA  < 0.3 ng.ml-1hr-1, the median PRA in the present study on the high salt 
diet, was 0.3 ng.ml-1hr-1. This may represent a regression to the mean and/or be 
a reflection of the inherent variability of PRA. Subjects of varying ethnicities 
were studied and this could have given rise to some confounding (although 
results were not influenced by adjustment for ethnicity), if there are ethnic 
differences in response to salt loading unrelated to PRA. Thus a future study 
should study a larger group of low renin subjects that would allow separate 




7.  Nitric Oxide Inhibition Sub-study 
 
 
The effects of acute inhibition of nitric oxide synthesis on urinary sodium 
excretion 
 
7.1    Introduction 
 
 
A tendency to sodium retention with suppressed plasma renin activity (PRA) is 
thought to be more common in subjects of African ancestry than in white 
subjects and may account for a greater prevalence and severity of hypertension 
in black compared to white subjects.  The underlying cause of the “low renin” 
phenotype is unknown, but, as described in Chapter 1, could be due to increased 
renal tubular reabsorption of sodium. NO is known to influence renal tubular 
absorption of sodium causing reduced reabsorption in the cortical collecting 
duct and therefore a potential naturiesis (Stoos, 1995). NO synthesised from 
eNOS in the endothelium of peri-tubular renal vasculature and/or NO released 
from other sources such as neuronal NOS (nNOS) could, therefore, influence 
sodium homeostasis. Reduced NO availability could therefore potentially 
explain reduced endothelial vasomotor function (e.g. reduced FMD), increased 
sodium reabsorption and low renin status, features that have been reported to be 
more common in subjects of African ethnicity. In this chapter I examined the 
influence of acute inhibition of NOS using NG-monomethyl-L-arginine (L-
NMMA), a non-specific inhibitor of NOS. I hypothesized that, if NO 
availability is responsible for sodium homeostatis and reduced NO availability 
contributes to a low renin state that a) acute NOS inhibition would reduce 
sodium excretion and b) effects of L-NMMA to reduce sodium excretion would 




7.2    Methods 
 
Subjects were a sub-group (n=40) of those studied in Chapter 5. Subject 
characteristics are shown in Table 8.  Subjects attended the vascular laboratory 
in the morning at approximately 08:00 after an overnight fast. Venous cannulae 
were inserted for drug administration and blood sampling and subjects 
commenced an oral water load of 200ml per hour. After 30 min lying semi-
supine, hourly urine collections were commenced. After 2 hours, subjects 
received an intra-venous infusion of the NO synthase inhibitor NG-monomethyl-
L-argine (L-NMMA, 3mg/Kg over 5 min), following which hourly urine 
collections were continued for a further 2 hours. Blood pressure was monitored 
using an oscillometric monitor (Omron 705CP) before and at 5 minute intervals 
for 20 minutes and then, 1 hour and 2 hours after the infusion of L-NMMA. Six 
subjects attended on a separate occasion and received saline placebo instead of 
L-NMMA. Urinary sodium (UNa), plasma sodium (PNa) urinary creatinine (UCR) 
and plasma creatinine (PCr) concentrations were measured in an accredited 
laboratory. To take into account variation in sodium intake, fractional urinary 
sodium excretion (FENa) was calculated from urinary and plasma values 
according to the formula:  








7.3    Statistical analysis 
 
Values of FENa at baseline and after infusion of L-NMMA/placebo were taken 
as the average of those obtained for the 2 hours before and after infusion of L-
NMMA/placebo respectively. Values of FENa after L-NMMA/placebo were 
compared with baseline values by Student’s paired t-test. The relation of the 
change in FENa from baseline after L-NMMA to PRA was examined using 
multiple regression analysis using log-transformed values of PRA as a 
continuous variable and, using ANOVA, across 3 categories of PRA: < 0.5, 0.5 
– 1.0 and > 1.0 ng/mL/h, corresponding to approximate tertiles of the 
distribution of PRA. In both analyses, baseline values of FENa were included as 
a covariate and an additional model was examined in which age, sex and 
















7.4    Results 
 









Age                  (Years) 
 
30(10) 
BMI               (Kg m-2) 26.4(4.7) 
Waist: Hip 0.81(0.07) 





Total Chol.  (mmol/L) 4.2(1.0) 
LDL              (mmol/L) 2.41(0.78) 
HDL             (mmol/L) 1.54(0.39) 
TAG             (mmol/L) 0.73(0.39) 
Glucose        (mmol/L) 4.5(0.6) 
Serum Na     (mmol/L) 140(2.0) 
Serum K       (mmol/L) 4.1(0.2) 
Creatinine    (mmol/L) 80(15) 
PRA                (ng ml-1hr-1) 1 0.9 (0.41.2) 
Urine Na: Cr 11.5(5.0) 
  
BMI, body mass index; BP, blood pressure; LDL, low density lipoprotein; HDL, 
high density lipoprotein; TAG, triacylglycerol; Na, sodium; K, potassium; PRA, 
plasma renin activity; Urine Na:Cr, urine sodium to creatinine ratio. 







Haemodynamic effects of LNMMA 
Administration of a saline vehicle was without significant effect on heart rate or 
blood pressure. After L-NMMA there was a small but significant increase in 
blood pressure from 122±2.6/74±1.8 mmHg at baseline to 126±2.5/77±2.0 
mmHg 15 min after L-NMMA (each P<0.001) and decrease in heart rate from 
61±1.4 to 56±1.1 bpm (P<0.0001).  
 
 
Effects of L-NMMA on renal sodium excretion and relation  
to PRA 
FENa did not change significantly after saline placebo (0.80±0.09 vs 
0.85±0.10% at baseline and after placebo respectively). However, after L-
NMMA, FENa decreased from 0.64±0.03 to 0.57±0.03% (P<0.0001), 
corresponding to a 12% reduction in FENa. The reduction in FENa by L-NMMA 
was significantly positively correlated with PRA (Figure 15) when adjusted for 
baseline values of FENa alone (P<0.01) or baseline values of FENa, age, sex and 
ethnicity (P<0.05). Thus, in subjects with PRA > 1.0 ng/mL/h, L-NMMA 
reduced FENa by 29.6±5.5% but in subjects with PRA < 0.5 ng/mL/h, L-NMMA 







Figure 15: Change in fractional excretion of sodium (FENa) after NO synthase 




































In conclusion, this study suggests that, in asymptomatic normotensive subjects, 
renal sodium excretion is, in part, regulated by endothelium-derived or other 
peritubular source of NO and that reduced NO availability may underlie sodium 
retention and low PRA. Interventions to increase endogenous NO availability 
and /or NO donors should be explored as treatments to prevent or treat 





















7.6    Discussion 
 
Recent findings pointing to a role of NO in renal tubular sodium excretion, raise 
the possibility that NO availability might be a determinant of sodium excretion 
and hence renin status. To examine this possibility I assessed the response of 
NO synthase inhibition on urinary sodium excretion, reasoning that reduced 
availability of NO would be associated with reduced response to NO synthase 
inhibition. The NO synthase inhibitor L-NMMA markedly reduced urinary 
sodium excretion. This confirms earlier observations in a small cohort of 
asymptomatic subjects that tonic release of NO from the renal vasculature or 
elsewhere is involved in regulation of sodium excretion (Bech, 1998).  
Importantly, the effect of L-NMMA to inhibit sodium excretion was reduced in 
subjects with low PRA. Taken together, the effect of L-NMMA to inhibit 
sodium excretion and impaired anti-natriuretic effects of NO synthase inhibition 
in subjects with low PRA suggest that vascular NO availability is a major 
determinant of sodium balance and renin status with low renin status relating to 
reduced NO availability.  Results of the study appear to contradict findings of 
Davidson et al. who reported that, after sodium depletion with furosemide, L-
NMMA infusion caused an increase in PRA (Davidson, 1999). However, pre-
treatment with furosemide makes this study difficult to interpret because 
subjects may not have been in sodium balance. Further work to examine the 
anti-natriuretic effect of L-NMMA during low and high salt diets will be 






A potential role of NO in regulation of sodium balance and renin status has 
important implications. In the presence of risk factors such as obesity, insulin 
resistance, dyslipaemia and diabetes all of which reduce NO availability, it 
provides an additional mechanism underlying the association of these 
conditions with hypertension. It suggests that treatments that increase 
endogenous NO availability and/or NO donors may be useful in reducing 
sodium retention. In this regard it is notable that NO donors are particularly 
effective in increasing PRA, with effects similar to diuretics and, when used in 
heart failure, are thought to offer greater clinical benefit when used in black 
compared to white subjects (Taylor, 2004). Future studies should explore 
whether other co-morbidities that are associated with low renin are also 
associated with sodium retention and low PRA and whether interventions that 
modulate NO availability will influence PRA. One possibility would be to use 
methodology described by Forte et al (Forte, 1998) to measure whole body NO 
production as well as indirect measures of endothelium derived NO production, 
such as FMD, to determine whether interventions such as weight loss or “statin” 
treatment will increase NO production and reduce sodium retention.  
 
A decline of PRA with age is well recognized (Tsumoda, 1986). Various 
mechanisms have been hypothesized to account for this such as age-related 
alterations of the kidney (decreased number of functional nephrons) that could 
influence the active to inactive plasma renin ratio (Weidmann, 1975), 
diminished synthesis of angiotensin by the liver (Leubel, 2008) and (in women) 
decreased levels of estradiol and progesterone (hormones that both stimulate 




also provides a potential explanation for the association of ageing (a major 
determinant of NO availability (Di Massimo, 2006)) with sodium retention, 
diminished PRA and higher blood pressure. 
 
These results also have implications for the interpretation of studies on 
endothelial function where an NO mediated vasodilator response such as FMD 
is used as a measure of generalized endothelial cell function. It is likely that, 
particularly in multi-ethnic cohorts and in hypertension studies, FMD relates to 
renin status (which is rarely measured). In subjects with essential hypertension, 
there are divergent findings with regard to measures of endothelial function: 
some studies report impaired and others preserved endothelial function. It is 
possible that these findings are explained by differing renin status of 
hypertensive groups in the different studies. Whilst sodium retention and low 
renin status are associated with greater prevalence and severity of hypertension 
and stroke it does not necessarily associate with increased incidence of coronary 
artery disease. Furthermore, recent studies indicate that endothelium-derived 
NO availability, as measured by FMD, is not independently related to 
cardiovascular outcomes and it is possible that NO availability is a more 
important determinant of sodium balance than of atherogenesis or progression 
of atherosclerotic disease. 
 
This study is subject to a number of important limitations. First we studied a 
cohort of apparently asymptomatic subjects to examine the potential role of NO 




differ in subjects with neurohormonal or renal hypertension/disease such as 
primary aldosteronism where aldosterone may be the dominant determinant of 
sodium balance. Finally, the NO synthase inhibitor we used is non-specific, 
inhibiting all NOS isoforms including eNOS and neuronal NOS. Thus we 
























8. THESIS DISCUSSION 
 
 
8.1 Overview  
 
 
As noted in Chapter 1, there are well-established differences in CVD risk and 
events between black and white ethnic groups and these differences account for 
significant health disparities. Both traditional and non-traditional risk factors are 
thought to play a role (Muntner, 2005). One major risk factor appears to be the 
relatively higher prevalence of hypertension in black compared to white 
subjects which may contribute to the higher mortality and morbidity observed 
in black compared to white groups; especially in relation to haemorrhagic 
stroke. It has been mentioned earlier that this difference is likely to diverge 
further if interventions targeted at a regional, national and international level are 
not implemented. A subtype of the hypertension epiphenomenon, salt sensitive 
hypertension, has been clearly described as especially sensitive to salt (NaCl) 
intake. Renin, a hormone involved in sodium regulation, has been shown by a 
number of investigators to be lower in black compared to white subjects in both 
normotensive and hypertensive subjects. This was confirmed in normotensive 
subjects in Chapter 5 where a significant difference in prevalence of “low” 
renin” as defined by PRA < 0.3 ngml-1hr-1 (black: 54% vs. 6% in white) was 
observed. Although less extensively studied than renin status and salt-sensitive 
hypertension, another recognized difference between black and white ethnic 
groups is a difference in vascular function, particularly endothelium-derived, 
NO-dependent vascular function (Bild, 2002). Since NO is recognized to 




endothelium-derived NO from eNOS, or another peritubular source of NO 
could represent a common factor linking sodium homeostasis with vascular 
function and structure (Romero, 1992).  
 
In this thesis, I have looked for differences between black and white ethnic 
groups in blood pressure, measures of vascular structure (CIMT and arterial 
stiffness as measured by PWV), vascular function (FMD and GTND) and 
sodium homeostasis; examined blood pressure and vascular responses to 
modulation of dietary salt; and effects of inhibition of NO synthase inhibition 
on renal sodium excretion in a white/black ethnic groups in South East London. 
The hypothesis that there is a causal relationship between NO availability, renal 
sodium handling and vascular dysfunction was investigated by relating effects 
of NO synthase inhibition and NO mediated vasodilation as measured by FMD 















8.2 Sodium homeostasis and ethnicity 
 
 Renin status and 24-hour urinary sodium were measured in Chapter 5. Previous 
investigators have used 24 hour-urine collections as a measure of usual sodium 
intake. Although some investigators have reported higher levels of dietary salt 
intake in black compared to white ethnic groups (Cappuccio, 1997), we 
observed similar 24 urinary sodium excretion and therefore, by extrapolation, 
sodium intake. However, we studied a relatively homogenous socioeconomic 
group of subjects recruited mainly from higher educational establishments. 
Differences in sodium intake in other studies may have been due, at least in 
part, to differing socioeconomic status and different diets. PRA was not 
correlated with 24-hour sodium excretion and differences in 24-hour sodium 
excretion did not account for ethnic differences in PRA, which remained 
significantly lower in black compared to white subjects when adjusted for 24-
hour sodium excretion. Thus lower PRA in black compared to white subjects in 
our study is likely due to renal sodium handling rather than dietary intake. This 
is consistent with previous studies where no correlation between PRA and 











8.3 Vascular structure and function in relation to ethnicity 
 
In Chapter 5, I looked for differences in blood pressure, FMD, GTND, CIMT 
and carotid-femoral PWV in relation to self defined ethnicity.  FMD is of 
particular interest since it is mediated almost exclusively by eNOS. Although 
FMD tended to be lower in black compared to white subjects, the difference did 
not reach statistical significance. However, FMD was significantly correlated to 
PRA.  Whilst this could have occurred as a result of confounding, the 
relationship was not affected by adjustment for other risk factors (including 
ethnicity) known to be associated with FMD. This relationship between FMD 
and PRA, therefore, suggests a relation between sodium hemostasis and NO-
dependent vascular function. Vasodilation to the NO donor GTN was similar in 
the two ethnic groups and was not significantly correlated with PRA, suggesting 
that any relation between sodium homeostasis and vascular function arises as a 
result of the availability of endothelium-derived (or other endogenous source of 
NO) rather than the response to NO.  CIMT, a measure of vascular structure 
thought to be a sub-clinical measure of atherosclerosis and/or a measure of 
vascular smooth muscle hypertrophy was significantly greater in black 
compared to white subjects. Differences seen in CIMT were not explained by 
PRA, BP or FMD. This suggests structural changes in the arterial wall are 
driven, at least in part, by factors other than sodium retention, BP and NO 
availability. However, we observed no correlation with other risk factors that 
could explain the difference in CIMT between the ethnic groups. This is 
consistent with previous studies (Fulsom, 2008) that have shown no correlation 




CIMT in African subjects. By contrast to CIMT, PWV was not significantly 
different between black and white subjects. PWV is thought to be driven mainly 
by blood pressure and this is consistent with little difference in blood pressure 

























8.4 Relation between vascular function and sodium  
 homeostasis 
 
The key finding of this thesis that FMD is independently related to PRA could 
have arisen because sodium retention impairs NO availability.  Sodium 
retention could for example increase oxidative stress and impair eNOS derived 
NO availability or there could be a direct interaction between renin and 
eNOS/NO. However, an alternative explanation is that NO availability 
determines sodium homeostasis. A number of studies in isolated cells and in 
animal models suggest that NO inhibits renal tubular absorption (Davidson, 
1999). It might also be suggested that another distinct factor might regulate both 
NO bioavailability and sodium excretion. Endothelial dysfunction has been 
shown in previous studies (Di Massimo, 2006)) to be associated with chronic 
inflammation and thus inflammatory mediators may represent a possible 
candidate. To distinguish between these possibilities I examined the influence 
of changing salt intake on FMD and the influence of acute inhibition of NOS on 












8.5 Modulation of dietary Salt intake 
 
In Chapter 6, I examined effects of modulation of dietary salt intake on BP, 
renin status and FMD. Compared to salt restriction, salt loading decreased renin 
and increased BP but had no significant effect on FMD. This contrast with 
results in a similar dietary sodium intervention study Dickenson et 
al.(Dickinson, 2011) These investigators randomized forty-one subjects to a 
low (50 mmol/day Na) vs. a “usual diet” (150 mmol/day Na).  They 
demonstrated significant changes in both FMD (4.89 +/- 2.42%) in the low salt 
diet vs. (3.37 +/- 2.1%) in the usual salt group (P=0.02). In this study, 
participant’s renin status was not characterized. However, the geographical 
location of this study means that it was likely that the participant’s PRA was 
higher than in our study. Although a lack of effect on FMD in my study could 
be due to a type 2 error, the difference between my findings and those of 
Dickenson et al may be due to lack of effect of additional sodium loading in a 
state where there is already sodium retention. In this case, the finding of a lack 
of effect of modulation of sodium intake on FMD, suggests that, if there is a 
link between NO availability and sodium homeostasis, it is unlikely to be due to 
sodium retention influencing NO availability, in subjects with low renin as in 









8.6 Influence of NO synthase inhibition on urinary sodium  
 excretion 
 
To test the hypothesis that NO availability influences sodium homoeostasis 
directly, thus explaining the link between FMD and renin status, I examined the 
influence of NO synthase inhibition on urinary sodium excretion in Chapter 7.  
Acute eNOS inhibition with L-NMMA reduced urinary sodium excretion and 
did so in a manner that was greater in subjects with higher compared to lower 
renin. This suggests that NO availability influences sodium homeostasis 
through renal sodium handling.  Relative lack of effect of NOS inhibition in 
subjects with lower renin may be due to low NO availability due to low basal 
NO synthesis in those subjects and /or to increased NO destruction and lead to 
















8.7    Synthesis and interpretation of experimental findings 
 
In summary, the main experimental results from Chapters 5, 6 and 7 are that: 
• FMD is independently correlated with renin status. 
• Salt modulation does not influence FMD in subjects with low renin. 
• Acute NOS inhibition impairs sodium excretion to a degree that relates to 
PRA. 
 
These experimental findings support the hypothesis that: 
• NO availability is a determinant of sodium homeostasis.  
• Reduced NO availability may contribute to the tendency for reduced 
endothelium-dependent vascular function and sodium retention in subjects 
















8.8 Implications – Clinical Pharmacology and Therapeutics 
 
Current management of hypertension in most major guidelines, such as British 
Hypertension Society (BHS) and the National Institute for Clinical Excellence 
(NICE), advocate both lifestyle and pharmacological treatment.  
 
One lifestyle change advised is dietary interventions to reduce sodium 
consumption. The direct link between dietary salt intakes and hypertension has 
been demonstrated in prospective and retrospective studies. This relationship 
may be even more critical in low renin states. In the Dietary Approaches to Stop 
Hypertension – Salt diet (DASH- Salt) a sub study of DASH, participants were 
restricted to 3g, 2.4g and 1.5g of sodium for 30 days. The lowest salt diet 
produced the greatest reduction in BP of approximately 8.9/4.5 mmHg. 
 
Pharmacological management of hypertension has principally been divided into 
drugs contributing to natriuresis and those causing arteriolar relaxation. The 
former has been cardinal in the management of low renin (salt sensitive) 
hypertension and includes both thiazide diuretics and aldosterone antagonists. 
Considering the arguments presented in this thesis, with the possible role of NO 
availability in sodium handling, drugs increasing NO availability may also play 
a role in hypertension management in this group.  
 
The HMG-Co A reductase inhibitors, or “statins”, are thought to have 
pleotropic effects in increasing NO bioavailability. Statins are thought to have a 




subjects with low renin in whom they might reduce sodium retention. NO 
donors like glyceryl trinitrate might also be more efficacious in patients with 
low renin and it is notable that they are thought to provide more benefit to black 
compared to white patients with heart failure (Taylor, 2004). 
 
Diminished availability of NO in association with risk factors traditional and 
novel could lead to increased risk not only through pro-atherogenic effects 
within the vascular endothelium but through sodium retention; this might 
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1. Study Title 
Ethnic differences in renovascular function 
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volunteer at low risk of cardiovascular disease.  
 
5. Do I have to take part? 
It is up to you whether or not you want to take part. If you decide to take part 
you will be given this information sheet to keep and asked to sign a consent 
form. However, you are still free to withdraw at any time and without giving a 
reason.  
 
6. What will happen to me if I take part? 
If you decide to take part you will be asked to attend the department on one or 
two separate occasions.   
On the first visit (10 minutes) we will complete your consent form and fit you 
with an automatic blood pressure monitor designed to be worn with a loose 








You will be asked to return for visit 2(2 hours) to have the blood pressure 
monitor removed and to return the urine collection. In addition, on the second 
visit we will ask you to attend in the morning having fasted from midnight. We 
will take measurements of your height, weight, waist circumference and blood 
pressure. We will take a blood sample to check your cholesterol and other 
markers of cardiovascular risk and hormones that regulate sodium balance. We 
will make some measurements of the health of your arteries by using an 
ultrasound scanner to look at arteries in your arm and neck. We will repeat the 
ultrasound measurements on the arm before and after inflating a blood pressure 
cuff for 5 minutes and after placing a drop of a drug glyceryl trinitrate on your 
tongue. Inflating the blood pressure cuff causes a feeling of tingling in the arm 
and is slightly unpleasant. Glyceryl Trinitrate is a standard drug used to relax 
arteries. It can cause dizziness and headache but the dose we will use is very 
low and no side effects have been recorded with this low dose. We will also 
record your pulse in the finger, arm and thigh by using a blood pressure cuff.  
The visit will take about 2 hours. 
Depending on the results from the first visit, you may be asked to participate in 
a second study if you wish to do this.  
 
7. What do I have to do? 
You will need to lie still during the measurements. 
 
8. What are the possible disadvantages and risks of taking part? 
 
• You will have the discomfort of having the blood sample. 
• We may discover that you have high blood pressure and/or high 
cholesterol that requires further investigation/treatment. If so we will ask 
you to contact your GP to arrange this. 
• The ultrasound test might reveal some thickening of the arteries that 
requires further investigation/treatment. If so we will ask you to contact 
your GP to arrange this. 
 
9. What are the possible benefits of taking part? 
You will have your blood pressure and cholesterol checked. 
 
10. What if new information becomes available? 
Sometimes during the course of a research project, new information becomes 
available. If new information becomes available that has implications for any 
treatment or investigation that you should receive we will contact yourself and 
your GP. 
 
11. What if something goes wrong? 
If you are harmed by taking part in this research and this is found to be due to 
someone’s negligence, you have grounds for legal action and compensation. In 
addition if you have any complaints about a member of the study team we 
would ask you to inform another member of the study staff about your concerns. 
 




All information that is collected about you during the course of the study will be 
kept strictly confidential. Any information that leaves the hospital will have your 
name and address removed. For this reason, on entering the study you will be 
assigned a unique patient number that will be used together with your sex and 
date of birth to identify study documents. If you agree, your GP will be informed 
of your participation in the trial. 
 
 
13. What will happen to the results of the research study? 
The results from the study may be published by a medical journal and/or 
presented to the regulatory authorities. This will be done confidentially and 
under no circumstances will your name be disclosed.  
 
14. Who is organising and funding the research? 
The study is being organised and funded by the Cardiovascular Division of 
King’s College London and will be performed in the Department of Clinical 
Pharmacology, St Thomas’ Hospital.  
 
15. Who has reviewed the study? 
The ethics for this study has been reviewed by St. Thomas’ Hospital NHS 
Research Ethics Committee. 
 
16. Contact for further information 
If you have any further questions or queries about any aspect of the study at 
any time, then please do not hesitate to contact Dr. Kenneth Connell (020 7188 
4770 normal working hours). Thank you for considering taking part in the study. 
If you decide to take part in the study you will be given a copy of the subject 























APPENDIX 3 – PATIENT INFORMATION SHEET 2 
 
 









Department of Clinical Pharmacology  
 

































Ethnic Differences in Renovascular Function 
Participant Information Sheet: blood pressure and ultrasound study 
07/H0802/135 
 (version 1.1  08-02-08) 
 
 
1. Study Title 
Ethnic differences in renovascular function 
 
2. Invitation Paragraph 
You are being invited to take part in a research study. Before you decide, it is 
important for you to understand why the research is being done and what it will 
involve. Please take time to read the following information carefully and discuss 
it with others if you wish. Ask us if there is anything that is not clear, or if you 
would like more information. Take time to decide whether or not you wish to 
take part. 
 
3. What is the purpose of the study? 
Black African and Afro-Caribbean subjects have, on average, a greater risk of 
a stroke than white subjects living in South London. This may be because 
black subjects have higher blood pressure and arteries that relax less readily in 
response to stress than white subjects. These differences may, in turn, be due 
to greater retention of sodium by the kidney in black compared to white 
subjects. The purpose of this study is to compare blood pressure and arterial 
function in relation to kidney function in black and white subjects. This will help 
us to find out why black subjects are more at risk of stroke and will help us to 
prevent stroke in both black and white subjects. 
 
4. Why have I been chosen? 
You are being invited to take part in the study because you are a healthy 
volunteer at low risk of cardiovascular disease.  
 
5. Do I have to take part? 
It is up to you whether or not you want to take part. If you decide to take part 
you will be given this information sheet to keep and asked to sign a consent 
form. However, you are still free to withdraw at any time and without giving a 
reason.  
 
6. What will happen to me if I take part? 
If you decide to take part you will be asked to attend the department on four 
separate occasions.  One the first visit you will receive general information 
about the study as well as a dietary consult.  You will be given detailed 
instructions on how to avoid high salt content foods. In addition, you will be 
given a 24hr urine collection and blood pressure monitor to be used two days 
before your next visit a week later. This visit should last approximately 30 
minutes.  
On visit 2, at the end of the first week, we will make some measurements of the 
health of your arteries by using an ultrasound scanner to look at arteries in your 
arm and neck. We will repeat the ultrasound measurements on the arm before 
and after inflating a blood pressure cuff for 5 minutes and after placing a drop 
of a drug glyceryl trinitrate on your tongue. Inflating the blood pressure cuff 




Trinitrate is a standard drug used to relax arteries. It can cause dizziness and 
headache but the dose we will use is very low and no side effects have been 
recorded with this low dose. We will also record your pulse in the finger, arm 
and thigh by using a blood pressure cuff.   Finally, we will take a blood sample 
to check your cholesterol and other markers of cardiovascular risk and 
hormones that regulate sodium balance. This visit will take about 2 hours. 
 
You will then be asked to take either salt tablets or placebo (dummy tabs) for 
two weeks each (5 tabs x 4 times daily) so that you will either be taking a low 
or high salt diet for that period. We will keep in touch with you by phone to 
check that you are happy with the diet and to offer further advice. The order in 
which you take placebo versus salt tablets will be determined ion a similar 
matter to tossing a coin. 
 
At the end of the third and fifth weeks (visits 3 and 4) you will be asked to 
attend the laboratory to have repeated blood and urine test, blood pressure 
and ultrasound measurements. 
 
A high salt diet is known to cause high blood pressure but when taken for just 




7. What do I have to do? 
You will need to lie still during the measurements. 
 
8. What are the possible disadvantages and risks of taking part? 
 
• You will have the discomfort of having the blood sample. 
• We may discover that you have high blood pressure and/or high 
cholesterol that requires further investigation/treatment. If so we will ask 
you to contact your GP to arrange this. 
• The ultrasound test might reveal some thickening of the arteries that 
requires further investigation/treatment. If so we will ask you to contact 
your GP to arrange this. 
 
9. What are the possible benefits of taking part? 
You will have your blood pressure and cholesterol checked. 
 
10. What if new information becomes available? 
Sometimes during the course of a research project, new information becomes 
available. If new information becomes available that has implications for any 
treatment or investigation that you should receive we will contact yourself and 
your GP. 
 
11. What if something goes wrong? 
If you are harmed by taking part in this research and this is found to be due to 
someone’s negligence, you have grounds for legal action and compensation. In 
addition if you have any complaints about a member of the study team we 





12. Will my taking part in this study be kept confidential? 
All information that is collected about you during the course of the study will be 
kept strictly confidential. Any information that leaves the hospital will have your 
name and address removed. For this reason, on entering the study you will be 
assigned a unique patient number that will be used together with your sex and 
date of birth to identify study documents. If you agree, your GP will be informed 
of your participation in the trial. 
 
13. What will happen to the results of the research study? 
The results from the study may be published by a medical journal and/or 
presented to the regulatory authorities. This will be done confidentially and 
under no circumstances will your name be disclosed.  
 
14. Who is organising and funding the research? 
The study is being organised and funded by the Cardiovascular Division of 
King’s College London and will be performed in the Department of Clinical 
Pharmacology, St Thomas’ Hospital.  
 
15. Who has reviewed the study? 
The ethics for this study has been reviewed by St. Thomas’ Hospital NHS 
Research Ethics Committee. 
 
16. Contact for further information 
If you have any further questions or queries about any aspect of the study at 
any time, then please do not hesitate to contact Prof. PJ Chowienczyk: Tel 
0207 718-81502     (normal working hours). Thank you for considering taking 
part in the study. If you decide to take part in the study you will be given a copy 
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Ethnic Differences in Renovascular Function 
Participant Information Sheet: L-NMMA study 
 (version 1.1  08-02-08) 
 
 
1. Study Title 
Ethnic differences in renovascular function 
 
2. Invitation Paragraph 
You are being invited to take part in a research study. Before you decide, it is 
important for you to understand why the research is being done and what it will 
involve. Please take time to read the following information carefully and discuss 
it with others if you wish. Ask us if there is anything that is not clear, or if you 
would like more information. Take time to decide whether or not you wish to 
take part. 
 
3. What is the purpose of the study? 
Black African and Afro-Caribbean subjects have, on average, a greater risk of 
a stroke than white subjects living in South London. This may be because 
black subjects have higher blood pressure and arteries that relax less readily in 
response to stress than white subjects. These differences may, in turn, be due 
to greater retention of sodium by the kidney in black compared to white 
subjects. The purpose of this study is to compare blood pressure and arterial 
function in relation to kidney function in black and white subjects. This will help 
us to find out why black subjects are more at risk of stroke and will help us to 
prevent stroke in both black and white subjects. 
 
4. Why have I been chosen? 
You are being invited to take part in the study because you are a healthy 
volunteer at low risk of cardiovascular disease.  
 
5. Do I have to take part? 
It is up to you whether or not you want to take part. If you decide to take part 
you will be given this information sheet to keep and asked to sign a consent 
form. However, you are still free to withdraw at any time and without giving a 
reason.  
 
6. What will happen to me if I take part? 
If you decide to take part you will be asked to attend the department on one 
occasion. At this visit a cannula (small plastic tube) will be placed in a vein in 
your arm to allow us to give you a drug called L-NMMA. This drug temporarily 
stops the production of the substance nitric oxide that controls the relaxation of 
arteries and also the absorption of sodium by the kidney. L-NMMA is a drug 
that is commonly used for investigations of this sort. It is theoretically possible 
that you could have an unexpected reaction to L-NMMA but no adverse effects 
have been reported and it has been given to many hundreds of subjects. Before 
and after we give the L-NMMA we will make some measurements of the health 
of your arteries by using an ultrasound scanner to look at arteries in your arm. 
We will monitor your blood pressure and also the amount of blood your heart 
pumps by asking you to take a few breaths of an inactive tracer gas by breathing 
through a mouthpiece at regular intervals. We will also collect your urine for a 




means that the whole visit will take about 4 hours during which you will be 
lying on a bed able to read, listen to music or the radio. 
7. What do I have to do? 
You will need to lie still during the measurements. 
8. What are the possible disadvantages and risks of taking part? 
 
• You will have the discomfort of having the blood sample and cannula 
insertion. 
• It is theoretically possible that you could have an unexpected reaction to 
L-NMMA but no adverse effects have been reported and it has been 
given to many hundreds of subjects. 
 
9. What are the possible benefits of taking part? 
You will be helping the advancement of scientific research. 
 
10. What if new information becomes available? 
Sometimes during the course of a research project, new information becomes 
available. If new information becomes available that has implications for any 
treatment or investigation that you should receive we will contact yourself and 
your GP. 
 
11. What if something goes wrong? 
If you are harmed by taking part in this research and this is found to be due to 
someone’s negligence, you have grounds for legal action and compensation. In 
addition if you have any complaints about a member of the study team we 
would ask you to inform another member of the study staff about your concerns. 
 
12. Will my taking part in this study be kept confidential? 
All information that is collected about you during the course of the study will be 
kept strictly confidential. Any information that leaves the hospital will have your 
name and address removed. For this reason, on entering the study you will be 
assigned a unique patient number that will be used together with your sex and 
date of birth to identify study documents. If you agree, your GP will be informed 
of your participation in the trial. 
 
13. What will happen to the results of the research study? 
The results from the study may be published by a medical journal and/or 
presented to the regulatory authorities. This will be done confidentially and 
under no circumstances will your name be disclosed.  
 
14. Who is organising and funding the research? 
The study is being organised and funded by the Cardiovascular Division of 
King’s College London and will be performed in the Department of Clinical 
Pharmacology, St Thomas’ Hospital.  
 
15. Who has reviewed the study? 
The ethics for this study has been reviewed by St. Thomas’ Hospital NHS 








16. Contact for further information 
If you have any further questions or queries about any aspect of the study at 
any time, then please do not hesitate to contact Dr. Kenneth Connell, 
Department of Clinical Pharmacology Telehone 020 7188 4470 or mobile 
07507492249. Thank you for considering taking part in the study. If you decide 
to take part in the study you will be given a copy of the subject information 









































REnoVascular function, Ethnicity, 
Renin and Endothelial Dysfunction  
 
REVERED CROSS SECTIONAL 
STUDY 
PARTICIPANT: 11 …… 
 
Screening questionnaire: REVERED 
 







Sex                        Male / Female Age yrs 






 PARTICIPANT GP CONTACT 
    Tel: HmWk: 
       
       Mobile: 
 







What is your ethnic group? (2001 Census) 
  
White         
British…………………………………………………………...⁪                                             
Irish……………………………………………………………...⁪ 
Any other white background (please state) ………………..........⁪ 
                          
Black or Black British         
Caribbean ……………………………………………………….⁪ 
African …………………………………………………….........⁪   





Please state your parent’s ethnicity? 
                                            





What is your country of birth?  ____________________ 
 
 
How long have you lived in the UK?  ____________________ 
 
 







Exclude if taking regular medications.  
 
  








Do you take the contraceptive pill?   YES ⁪    NO ⁪ 
 
If yes, which one?_____________________________________________ 
 
 
Do you take any inhalers?                 YES ⁪    NO ⁪ 
 
If yes, which one?_____________________________________________ 
 
 
Do you use recreational drugs?        YES ⁪    NO ⁪ 
                                                             Exclude                                   
 
Have you been diagnosed with anxiety, depression, diabetes I or uncontrolled 












Have you been diagnosed with sickle cell disease?                YES ⁪    NO ⁪ 
                                                                                                     Exclude                                   
 
Do you have sickle cell trait?                                YES ⁪   NO ⁪   DON’T KNOW ⁪ 
 
 
Does anyone in your family suffer from sickle cell disease?   YES ⁪ NO ⁪  
                                                                                                      DON’T KNOW ⁪ 
 
 
Are you pregnant?                                                                      YES ⁪    NO ⁪ 
                                                                                                     Exclude      
 
Have you given birth in the past 6 months?                         YES ⁪    NO ⁪ 
                                                                                                 Exclude      
 
Are you a smoker?                                                            YES ⁪    NO ⁪   
                                                                                            Exclude 
        
A non-smoker? (never smoked)                                      YES ⁪    NO ⁪   
 
Are you an ex-smoker?                                                    YES ⁪    NO ⁪   
                                                              
                                     No. years stopped:              No. per day:           No. of years: 
                                                                               (if <6 months exclude)    
 
How many units of alcohol do you consume per week? _________Excl. if >28 units 
♂ 
                                                                                             _________Excl. if >24 units 
♀ 




























Data Collection Form 
 
Date 1st Visit 
 
 
Date 2nd Visit Arrival Time: 
Height                                            
cm 
Weight                              
kg 
BMI                                        
kg/m2  
(exclude if <18 or 
>36kg/m2) 
Waist circumference:                    
cm 
 
Hip circumference:          
cm 
 
Waist: Hip Ratio 
Last Day of  
Menstrual Cycle              
days 
 Departure Time: 
 
 
(TIME………….) SEATED BLOOD PRESSURE 
 
Seated BP 30 mins     
 
35 mins 40 mins Mean 
SBP 
 
    
DBP  
 
   
HR 
 
    
 
 
(TIME: …………)PULSE WAVE MEASUREMENTS 
 
Carotid-Femoral distance:            cm 




(TIME STARTED: …………….)  Temp:  Room: ……………….     Skin: ……….. 
FMD   Filename …………………  GTN 
Filename…………Dose…….µg 
Baseline start       __________ (+ 1 min)  Baseline start       __________ (+ 1 min) 
 
Cuff up         __________ (+ 5 min)  GTN given         __________ (+ 5 min) 
 







Baseline Dia:  …….FMD%.............           Baseline 
dia:………GTND%............... 
 
Flow VTI HR Flow VTI HR 
Baseline 1   RH 15 secs   
Baseline 2   RH 45 secs   
Baseline 3   RH 60 secs   
RH  5 secs   RH 75 secs   












24 HOUR URINE  
 
U Na K Prot/Creat: Cortisol 
Na:Creat. K:Creat (mRNA)  
U Protein Volume (ml) Cortisone 
 Left  
measur
e  







e       



























        




        
IMT            
post(mm
) 
                   
Systolic 
        
                    
Post 
(mm) 
           
Diastolic 























































Glucose: mmol/L   T-Chol: mmol/L 
Creatinine: µmol/L   HDL: mmol/L 
Urea    TG: mmol/L 
Urea    LDL  
PRA    Sodium mmol/L 
Aldosterone    Potassium mmol/L 
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